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ABSTRACT
Background
Expanding the criteria for deceased organ donors increases the risk of delayed graft  function 
(DGF). DGF, especially when long lasting, complicates kidney transplant outcome. Liver 
transplant recipients are at an increased risk for kidney injury both before and aft er transplantation 
and renal dysfunction strongly associates with morbidity and mortality. Identifying kidney injury 
early is crucial in achieving favorable outcome aft er transplantation. However, there are currently 
no reliable methods for predicting kidney damage in transplant patients.
Neutrophil gelatinase-associated lipocalin (NGAL) is a novel marker for acute kidney injury 
(AKI). Th e aim of the study was thus to test whether donor and recipient urine and serum NGAL 
could predict DGF, prolonged DGF lasting >14 days, or quality of kidney function in non-
DGF transplantations, and whether plasma NGAL obtained prior to liver transplantation could 
predict prolonged kidney injury aft er liver transplantation.
Methods
Ninety-nine consecutive, deceased, heart-beating donors and their 176 adult kidney recipients 
were prospectively included. Serum and urine samples were collected from the donors before 
organ retrieval. From the recipients, serum and urine samples were collected at arrival to the 
transplant unit and in the mornings of days 1 and 14 aft er transplantation. Serum NGAL was 
analyzed using the enzyme-linked immunosorbent assay (ELISA) and point-of-care (POC) 
methods. Urine NGAL was analyzed using the ARCHITECT® method. For the liver study, all 
adult deceased donor liver transplant recipients (n=203) at our center during the years 2005 to 
2010 were included and pretransplant plasma NGAL was analyzed using the POC method. 
Results
DGF was seen in 70/176 patients. Th e duration of DGF was prolonged (>14 days) in 26 cases. 
Transplants with prolonged DGF had worse 1-year graft  survival (73%) compared to transplants 
with shorter DGF (100%, p=0.001).
Th e mean donor sNGAL was 218ng/mL and uNGAL 18ng/mL. Donor sNGAL and uNGAL 
concentrations correlated directly with donor plasma creatinine and indirectly with estimated 
glomerular fi ltration rate (eGFR). Donor NGAL did not predict DGF as such. High (>mean) 
donor uNGAL concentration associated with prolonged DGF and worse 1-year graft  survival 
(90.3%) compared to the low uNGAL group (97.4%, p=0.048). In a multivariate analysis, uNGAL 
and expanded criteria donor status emerged as independent risk factors for prolonged DGF. 
Recipient uNGAL was signifi cantly higher in patients with DGF compared to recipients with 
early graft  function (EGF) at all measured time points. Day-1 uNGAL predicted DGF and 
prolonged DGF with an AUC of 0.75. Day-1 uNGAL also predicted DGF in cases which seemed 
to have early function: in 15/112 cases with day-1 urine output >1L (AUC 0.70) and in 19/86 
cases with >50μmol/L decrease in creatinine on day 1 (AUC 0.74). In a multivariate analysis, 
day-1 uNGAL emerged as an independent predictor of DGF. 
Recipient sNGAL was signifi cantly higher in patients with DGF compared to patients with EGF 
at all measured time points. Day-1 sNGAL predicted DGF with an AUC of 0.85 and prolonged 
DGF with an AUC of 0.83. In a multivariate analysis, day-1 sNGAL emerged as an independent 
predictor of DGF.
In the liver transplant recipients, pretransplant pNGAL modestly correlated with creatinine and 
cystatin C levels eGFR. Th ere were no signifi cant diff erences in the mean pNGAL concentrations 
between patients with or without posttransplant AKI or a need for posttransplant renal 
replacement therapy. Th e mean pNGAL was signifi cantly higher among liver transplant patients 
with eGFR <60mL/min at three months aft er transplantation compared to those with eGFR >60 
mL/min (p=0.001).
Conclusions
Donor uNGAL measurements give additional value in the evaluation of donor kidney function 
and suitability for kidney donation. Recipient day-1 uNGAL predicts DGF when it is not clinically 
expected early on and prolonged DGF, which leads to poor graft  survival. Day-1 sNGAL predicts 
clinically signifi cant DGF. Measuring recipient sNGAL and uNGAL on the morning following 
kidney transplantation is therefore useful in individualizing patient care. Pretransplant pNGAL 
associates with reduced kidney function at three months aft er transplantation and helps in 
optimizing and individualizing patient care. 
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 1.  INTRODUCTION
Kidney transplantation is the best available treatment for end-stage renal disease (ESRD). It 
signifi cantly improves patients’ quality of life and has been reported to markedly decrease the 
risk of death compared to patients on maintenance dialysis (1). At Helsinki university hospital 
5-year kidney graft  survival is more than 80%. As the prognosis for patients on maintenance 
dialysis has improved, the number of patients needing a kidney transplant has increased, and 
the gap between supply and demand has widened. Consequently, the donor criteria have been 
expanded which has led to an increase in delayed graft  function (DGF) aft er transplantation. 
Liver transplantation is the standard and only curative treatment for patients with liver 
failure. Th e prognosis aft er liver transplantation has improved signifi cantly over the past 
decades: 75–85% of recipients have a functioning graft  at fi ve years aft er transplantation 
(2,3). Th is improvement results from advances in immunosuppression, organ preservation, 
surgical techniques and pretransplant treatment of patients with liver failure (4). Despite these 
improvements, liver transplant recipients are at an increased risk for kidney injury both before 
and aft er transplantation and renal dysfunction strongly associates with morbidity and mortality 
(5–7).
Both DGF and renal failure associated with liver failure are forms of acute kidney injury (AKI). 
AKI is a general term describing acute renal impairment of various, multifactorial origins and 
to varying degrees. Its pathogenesis is poorly understood, diagnostic methods inadequate, and 
treatment options limited. AKI infl icts a considerable health and economic burden (8–10). At 
present, DGF and AKI associated with liver disease cannot be predicted, diagnosed early, or 
treated. Th e exact molecular mechanisms also remain unknown. Being able to diagnose these 
conditions early would aid the development of new treatments. 
Neutrophil gelatinase-associated lipocalin (NGAL) is a new, noninvasive marker of AKI (11–21). 
NGAL has been proposed as a marker of DGF, as an association with NGAL and DGF has been 
found in studies where urine or serum NGAL had been measured very soon aft er transplantation 
(22–38). Th e role of NGAL in predicting AKI aft er liver transplantation has also been proposed 
(39–50). 
Th e aim of this study was thus to examine the role of NGAL in DGF in a large prospective study 
including both deceased kidney donors and recipients and to study whether NGAL measured 
from liver transplant recipients before transplantation predicts prolonged kidney injury aft er 
liver transplantation.
Introduction
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2.  REVIEW OF THE LITERATURE
Kidney transplantation is the only curative treatment for end-stage renal disease (ESRD). Th e 
results of kidney transplantation have signifi cantly improved over recent years. Th e outcome aft er 
transplantation depends on recipient factors, donor issues and events related to transplantation. 
However, the increasing age and cardiovascular morbidity of both recipients and donors, DGF, 
lack of effi  cient treatment for chronic allograft  nephropathy (CAN), and adverse eff ects of 
immunosuppressive drugs such as cancer, diabetes, and infection have a negative eff ect on long-
term results (51–53). 
2.1  Recipient factors aﬀ ecƟ ng kidney graŌ  survival 
Th e prevalence of patients on maintenance dialysis has grown far more rapidly than the growth 
rate of the general population due to the increasing age, morbidity—particularly diabetes—and 
longer life expectancy for patients with ESRD (54, 55). Th us, recipients have become older and 
more commonly have multiple chronic disorders infl uencing the long-term results aft er kidney 
transplantation. 
Age at the time of transplantation has a clear impact on graft  survival; an older age leads to inferior 
long-term outcomes (56). Cardiovascular disease is an independent risk factor for impaired graft  
survival and death (57–59). Time spent on maintenance dialysis also directly correlates with 
poorer long-term survival (59). An advantageous factor regarding graft  and patient survival 
is human leukocyte antigen (HLA) matching (52, 60). Th e presence of HLA antibodies, and 
especially donor specifi c antibodies, is associated with the occurrence of acute rejection (AR) 
and decreased graft  survival aft er transplantation (61, 62). Primary kidney disease, CAN and a 
recurrence of the primary kidney disease in the transplanted graft  are important causes of kidney 
graft  loss (52, 63). However, the most signifi cant cause for graft  loss is the death of the recipient 
(64, 65).
2.2  Donor factors aﬀ ecƟ ng kidney graŌ  survival
Th ere is a constant disparity between the need for and the availability of kidneys for 
transplantation; according to the Organ Procurement and Transplantation Network (OPTN) 
database, every year the number of patients added to the waiting list for kidney transplantation 
increases whereas the number of performed transplantations remains stable or even declines 
(66). For example, between 2000 and 2009 in the US alone 1,155,897 patients were added to the 
kidney waiting list, while only 125,968 (10.9%) received a transplant (67). Th e majority were 
deceased donor transplantations (68%) and every fourth kidney came from an expanded criteria 
donor (ECD) (67). Hence, there is a substantial need to increase the living and deceased donor 
pool. In Finland, the majority of donors are deceased donors, with only about 2–5% being living 
donors. 
Living donor kidneys are uniformly superior to deceased donor kidneys due to, for example, 
the possibility of a precise pretransplant evaluation of the donor and the donor kidney, lack 
of trauma causing brain death and the destructive eff ects of brain death, and very short CIT 
Review of the Literature
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(52). Th e limiting factor is fi nding a suitable and willing donor. Th e paired-donor exchange 
program is one example of how the living donor pool can be increased. It enables living donor 
kidney transplantation for those without a compatible kidney donor of their own; kidneys can 
be exchanged simultaneously between two to three, or even more, pairs (68). Additionally, 
de-sensitizing protocols enable transplantation across blood group and from an HLA-
incompatible donor (69,70). 
Th e selection criteria for deceased donors have also been widened, meaning that many older 
donors with comorbidities who would have previously been rejected are now accepted for 
transplantation. In the short term, this seems to result in a negative eff ect on the onset of graft  
function aft er transplantation. However, in historical data the improvement in recipient care 
seems to, at least partly, override this negative eff ect regarding 1-year graft  survival (71). 
Th ere are many defi nitions for ECDs, but the most commonly used classifi es ECDs as brain-dead 
donors older than 60 or older than 50 with more than one additional risk factor (hypertension, 
cerebrovascular accident as cause of death or plasma creatinine 1.5mg/dL/>132μmol/L) (72). 
Additionally, there are programs for accepting kidneys from donors aft er cardiac death (DCD), 
further adding to the potential donor pool. Not surprisingly, this has led to new problems, as the 
quality of donor kidneys has a clear impact on long-term outcome (53, 72–74). Th e use of ECD 
kidneys is associated with reduced recipient and graft  survival and increased incidence of DGF 
compared to standard criteria donor (SCD) kidneys (72, 75, 76). Interestingly, although the use 
of DCD kidneys is associated with increased occurrence of DGF and primary nonfunction, it 
does not seem to aff ect long-term results (77). However, not all ECDs are alike; some have very 
well-functioning kidneys without any histological changes in biopsies. Kidneys from very old 
deceased donors (>75 years) did not increase the risk of DGF or primary nonfunction if the 
donor had been healthy with no comorbidities such as cardiovascular disease (78). In addition, 
many non-donor related factors, such as cold ischemia time (CIT) and cold preservation, with 
or without machine pump perfusion, aff ect the results (79). Various algorithms have been 
developed to evaluate ECD donors but they also include non-donor related variables such as 
CIT and HLA match (80–83). In practice, these are not helpful for a clinician trying to decide 
whether to accept or reject a donor. Hence, there is a substantial need for new tools for assessing 
donor kidney quality.
SCD kidneys rarely have abnormalities in their kidney biopsies, but when ECD kidneys are used 
the issue of preexisting abnormalities becomes more relevant (53). A preimplantation donor 
kidney biopsy is thus helpful in deciding whether to transplant or discard an ECD kidney. Donor 
biopsies also provide important baseline information from the kidney that subsequent biopsies 
can be compared to (83, 84). Most donor biopsies show at most mild unspecifi c changes, most 
commonly global sclerosis, arterial sclerosis, tubular atrophy and interstitial fi brosis (71, 84). 
Th e data on whether histological changes correlate with graft  survival is controversial, yet some 
studies have found that the severity of histological changes correlates with graft  survival, vascular 
disease and fi brosis (53, 75, 81, 83, 84).
Th ere is no uniform prevailing practice concerning the use and allocation of ECD kidneys, as 
they are of somewhat inferior quality. A recent study found that transplanting ECD kidneys 
instead of SCD kidneys to patients <60 years old signifi cantly increased mortality (85). Generally, 
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age matching (old to old) is used and has been suggested to attenuate the eff ect (65, 85, 86). Age 
matching leads to worse outcome compared to transplantation from SCD in older patients, but 
overall the results are signifi cantly better compared to a long waiting time on maintenance dialysis 
(74, 85). Th e United Network of Organ Sharing (UNOS) Kidney Transplantation Committee has 
suggested a new allocation policy for ECD kidneys based on donor quality. Hopefully, this will 
help in increasing the donor pool further and optimize the use of ECD kidneys. 
2.3  TransplantaƟ on related factors aﬀ ecƟ ng kidney graŌ  
survival
Ischemia/reperfusion injury (IRI), AKI, DGF, immunosuppression and CAN all have a major 
impact on long-term graft  survival. 
2.3.1  Ischemia/reperfusion injury
All transplanted kidneys are subject to cold ischemia, warm ischemia and reperfusion resulting 
in direct cell death and increased infl ammatory response with ensuing cell death and tissue 
damage (Figure 1). Ischemia causes hypoxia and the accumulation of reactive oxygen species 
(ROS). Reperfusion presents the transplanted kidney to the hosts’ immune system, activating 
the innate and adaptive defense mechanisms, which target the graft  in multiple ways (87). 
Reperfusion additionally triggers a pathologic vasoconstriction, which is further augmented by 
increased endothelin levels (88, 89). 
Review of the Literature
Figure 1. Th e molecular eff ects of ischemia/reperfusion injury.
ROS=reactive oxygen species, ICAM=intercellular adhesion molecule, CXCR=CXC chemokine 
receptor, HO=heme oxygenase, TLR=toll like receptor, DC=dendritic cell, Treg=T regulatory cell, 
NF-kB=nuclear factor kappa-light-chain-enhancer of activated B cells.
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IRI mostly targets endothelial cells in the glomerulus and epithelial cells in the tubule (90). IRI 
predisposes the graft  to tubular cell necrosis and fi brosis, and increases immunogenity, thus 
causing AKI, DGF, rejection and CAN (91,92). However, it is not known how the dose of IRI is 
related to the degree of damage. T regulatory cells, graft  derived dendritic cells and microparticles 
play a role in protecting the graft  from IRI (93).
2.3.2  Acute kidney injury
In practice, all transplanted kidneys show changes comparable with changes seen in AKI. Th e 
degree of injury varies from clinically undetectable to DGF and primary nonfunction. AKI is 
a multifactorial condition leading to various degrees of renal failure with poorly understood 
pathogenesis and inadequate diagnostic tools to detect it early enough/in real time. AKI is 
associated with morbidity, mortality, prolonged hospitalization and increased costs (9, 10, 94).
Today, assessing kidney function is based on measuring serum/plasma creatinine levels and urine 
output. Various classifi cations can be used to assess and categorize AKI, but the most widely 
acknowledged and used are the RIFLE (Risk, Injury, Failure, Loss, Endstage) criteria (95), Acute 
Kidney Injury Network (AKIN) criteria (96), and KDIGO Clinical Practice Guideline for Acute 
Kidney Injury (94). Th ere are no applicable classifi cations for AKI in kidney transplantation as 
the recipients already have ESRD. Creatinine is a poor marker for AKI as it needs to be measured 
in a steady state, it reacts slowly to changes in kidney function and many non-renal factors 
aff ect its concentration (97–99). Th e hunt for a good kidney injury marker has been ongoing for 
decades, but so far nothing has undermined the position of creatinine. 
Fluid resuscitation is the most benefi cial and the only widely accepted treatment to prevent and 
attenuate AKI (100, 101). Dialysis treatment is of additional value in the presence of hyperkalemia, 
fl uid overload or metabolic acidosis. Of other treatments, intravenous sodium bicarbonate, 
levosimendan, N-acetyl cysteine administration before radiocontrast and natriuretic peptides in 
major surgery have all been shown to have somewhat promising results in alleviating AKI (102–
106). However, in general, therapies are lacking success, as the diagnosis is usually delayed and 
treatment cannot be targeted because the mechanisms behind AKI are still poorly understood. 
2.3.3  Delayed gra?  func? on
According to the Organ Procurement and Transplantation network database (http://optn.
transplant.hrsa.gov) the incidence of DGF is approximately 24.3%. However, the reported 
incidences of DGF vary from 4% when using living donor kidneys to more than 50% for deceased 
donor kidneys (107–109). DGF rarely complicates living donor transplantations. However, 
in deceased donor transplantation DGF aff ects a signifi cant number of transplantations: one-
third at our center (110). Th e rate of DGF is constantly rising as more ECDs are accepted for 
transplantation (74, 111, 112). 
DGF is a multifactorial condition in which many donor, recipient and transplantation related 
factors play a role. Th e precise mechanism behind DGF is still somewhat obscure but the key 
factors are donor brain death and the subsequent catecholamine and cytokine storm, IRI and 
the activation of innate and adaptive immune responses in the recipient (80, 113). Th ere are 
currently no means to predict DGF.
Review of the Literature
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Th ere are several defi nitions in the literature for DGF (108, 109). Th is lack of a uniform defi nition 
complicates the comparison of diff erent studies, hinders diagnosis and impedes the development 
of potential treatment. 
Th e most popular defi nition for DGF is the need for dialysis during the fi rst week aft er kidney 
transplantation. Between 1984 and 2007 this defi nition was used to defi ne DGF in 69% of 
reviewed studies (108, 109). It is simple and easy to use. However, it falsely includes patients 
needing one dialysis, for example due to high potassium levels or fl uid overload, and excludes 
patients with good diuresis without need for dialysis, but with slowly decreasing creatinine 
which does not require dialysis during the fi rst week. At our center, DGF has been defi ned using 
the Halloran et al. (114) defi nition: urine output <1L/24 hours for >2 days, or plasma creatinine 
concentration >500μmol/L throughout the fi rst week, or >1 dialysis session needed during the 
fi rst week. 
DGF increases the need for dialysis and post-transplant biopsies, increases the risk of AR and 
masks it, extends the duration of the post-transplantation hospital stay, increases the risk of CAN 
and causes considerable economic burden (110, 112, 115–118). Additionally, DGF has adverse 
long-term eff ects and is associated with increased mortality (113, 119). Not all studies have 
found an association between DGF and graft  survival and there is no general agreement on the 
ultimate eff ect of short DGF (lasting less than one week) on graft  survival. However, there is 
strong evidence concerning the damaging eff ect of prolonged DGF on graft  survival (112, 120, 
121). 
Risk factors for DGF are related to the donor (ECD, DCD, old age, female gender or obesity), 
transplantation (long warm and cold ischemia time or absence of machine perfusion), and 
recipient (obesity, diabetes, mode of and time on maintenance dialysis before transplantation, 
male gender or immune sensitization) (72,122–124). Th us, including these risk factors in a 
nomogram can help in risk assessment (80, 81). 
DGF cannot be treated. However, all patients with DGF should be biopsied to exclude AR and 
acute tubular necrosis (125). Ultrasound scanning should be performed to exclude hematomas, 
urinary tract obstruction or problems in the vessels of the graft . Other treatment during DGF 
consists of dialysis, sustaining hemodynamic stability and avoiding nephrotoxins (125). 
2.3.4  Immunosuppression
Immunosuppression has a major role in preventing rejection and improving short-term 
outcomes. Diff erent immunomodulating strategies have also enabled transplantation for 
highly sensitized recipients (126). Short-term outcomes aft er kidney transplantation were 
dramatically improved in the 1980s when calcineurin inhibitors (CNIs) were included in the 
immunosuppression (51, 127). However, immunosuppression has many side eff ects, such as 
direct nephrotoxicity to the graft , increased susceptibility to infections, and increased risk for 
malignancy, diabetes and cardiovascular disease (52). CNI nephrotoxicity can lead to progressive 
and irreversible fi brosis, sclerosis and deterioration in renal function (128). CNIs have a narrow 
therapeutic window and express notable variability in adsorption, distribution, metabolism and 
elimination (129). Th erefore, the use of these drugs is demanding and the through levels need 
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frequent monitoring. Consequently, various CNI-free or CNI-sparing therapies have emerged, 
which have not improved long-term outcomes (130–132). Th ere is a consensus that CNIs 
contribute to CAN development but it is unclear how big this impact is (127, 133). 
KDIGO guidelines suggest that immunosuppression aft er kidney transplantation should consist 
of triple therapy: CNI (cyclosporine A or tacrolimus), antiproliferative agent (mycophenolate 
mofetil), and steroids with or without induction therapy with induction agents, preferably 
interleukin 2 receptor antagonists (IL-2R) (125). 
2.4  AlleviaƟ ng ischemia/reperfusion injury
Timely diagnosis and management of post-transplant complications is essential for graft  survival. 
Alleviating IRI might help in preventing DGF.
2.4.1  Donor treatment
Brain death induces extensive metabolic changes, multiple organ dysfunction and widespread 
injury in the donor (134, 135). It generates systemic infl ammation that by the time of organ 
recovery will have lasted several hours (136, 137). Additionally, there are alterations in endocrine 
function, vascular regulation and coagulopathy, which further increase the infl ammation and 
hemodynamic instability (134, 138, 139). Limiting the time between brain death and organ 
procurement to less than 24 hours decreases the risk of DGF (140, 141). Early identifi cation 
and treatment of brain death related complications, such as diabetes insipidus and pulmonary 
edema, additionally improve the outcome of the transplanted organ in the recipient (142). 
2.4.1.1  Fluids
It is benefi cial to maintain a mean arteriolar pressure >70mmHg in all donors by fl uid resuscitation 
(143). Hydroxyethyl starch use has been found to associate with early graft  dysfunction and DGF 
in the kidney recipient (144, 145) in addition to its other negative eff ects. Using a large volume 
(>1250ml) of other colloids, for example albumin, has been found to associate with reduced risk 
for DGF (146). Hypernatremia in the donor commonly results from disturbed fl uid balance and 
induces osmolality and swelling, and aggravates IRI (147, 148). Hypernatremia >150 mmol/L 
has been found to associate with graft  dysfunction and loss aft er transplantation (147, 148).
2.4.1.2  Hormonal resuscita? on
Th e brain death induced catecholamine storm incapacitates the donors’ endocrine function, 
resulting in a considerable decrease in hormone levels including cortisol, thyroxine, insulin and 
vasopressin (149). Treating donors with intravenous steroids alleviates the eff ect of systemic 
infl ammation (150). In kidney recipients this was associated with better 1-year graft  survival and 
in liver recipients with amelioration of IRI and decreased incidence of AR (151, 152). However, 
not all studies have found these associations (153,154). 
Low levels of triiodothyronine and thyroxine have a major role in donor anaerobic metabolism 
and depletion of glycogen. Th e etiology is unclear but permanent damage to the hypothalamus is 
suggested as a possible cause. Treatment with triiodothyronine and thyroxin has been suggested 
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to result in a reversal from anaerobic to aerobic metabolism and stabilization and improvement 
of cardiac function (155,156). However, a recent meta-analysis found that treating donors with 
triiodothyronine did not have any benefi cial hemodynamic eff ects (149).
Additional use of desmopressin or vasopressin in diabetes insipidus has been found to be 
benefi cial in some studies (143). Nevertheless, the recent meta-analysis did not fi nd any 
advantageous eff ects of desmopressin administration and kidney function or outcome aft er 
transplantation (149). In the case of patients without diabetes insipidus, treatment with arginine 
vasopressin was found in one study to reduce the need for inotropes (157).
Brain dead donors are usually hyperglycemic as brain death increases gluconeogenesis and 
insulin resistance and decreases insulin secretion (149, 158). Hyperglycemia and high variability 
in blood glucose levels associate with decreased graft  function aft er transplantation (159, 160). 
Th erefore, aggressive management of hyperglycemia in the donor is recommended (UNOS 
guideline). 
2.4.1.3  Vasopressors
Dopamine is a neurotransmitter that has central and peripheral actions. Peripheral dopamine 
mediates blood fl ow, glomerular fi ltration rate, sodium excretion and catecholamine release. 
Hence, it is used as a vasopressor in acute situations and donor treatment. It also induces heme 
oxygenase-1, which catabolizes unstable iron and antagonizes free radical generation (87). One 
large multicenter study found that treating the donor with low dose dopamine vs. no dopamine 
treatment improved early kidney graft  function and decreased the incidence of DGF and 
prolonged graft  survival, but did not aff ect patient survival (161, 162). 
Donor epinephrine or adrenaline infusion associates with an increased risk for DGF (146). 
However, vasopressor support is imperative if hemodynamic status requires it (141, 143).
2.4.1.4  An? coagula? on
Brain death causes signifi cant disturbances in blood coagulation. Deceased organ donors 
are usually treated with anticoagulants to prevent thrombosis. It has been suggested that the 
prevalence of microscopic thrombosis is underestimated (163). In a pig model of kidney 
transplantation, it was shown that treating the donor with a thrombin inhibitor melagatran just 
before perfusion with University of Wisconsin solution might improve graft  survival (163, 164). 
Additionally, timely diagnosis and treatment of disseminated intravascular coagulopathy and 
other dysfunctions is needed (143).
2.4.2  Organ preserva? on
Preserving the kidney in cold buff er fl uid for the time of transportation helps to protect the 
kidney by decreasing metabolism, and reducing osmotic injury/edema and acidosis (87, 165). 
Th e UW solution is one of the most commonly used buff ers. It contains adenosine to improve 
aerobic metabolism and allopurinol to inhibit xanthine oxidase. 
Machine perfusion has been suggested to reduce the risk of DGF and improve 1-year graft  
survival aft er transplantation of both SCD and ECD kidneys (166). However, this was not found 
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in recent meta-analysis (167). Using extracorporeal membrane oxygenation in DCD has shown 
promising results in deducting DGF (168)
2.4.3  Recipient treatment
Many diff erent strategies such as ischemic preconditioning; stem cell therapies; molecules to 
prevent infl ammation, endothelial injury, and vasoconstriction; and complement regulators 
have been studied in experimental models to limit IRI and especially the reperfusion injury 
in the recipient. Only a few have been studied in humans, with very minor results. Adequate 
intraoperative fl uid treatment is one of the rare eff ective means to reduce the risk of DGF (87, 
169–174). 
2.4.3.1  Immunosuppression
Reperfusion activates the hosts’ innate immune system: macrophages and neutrophils migrate 
into the graft  and the complement cascade is activated, further activating the adaptive immune 
system, resulting in the formation of ROS and direct cell lysis (87, 173, 174). Targeting the 
recipients’ immune system before transplantation with induction therapy, for example using 
anti-CD25, anti-CD52, anti-CD3 or antithymocyte immunoglobulins, may decrease the 
incidence of DGF (87). Initiating CNIs before transplantation or in the early postoperative 
period does not seem to increase the risk of DGF or delay graft  recovery, despite previous beliefs 
(175).
Many molecules have anti-infl ammatory actions. Administrating these molecules to alleviate the 
eff ects of the activated immune system has been proposed to have a role in preventing DGF. 
However, small studies on erythropoietin, P-selectin and human annexin V homodimer have 
been performed without signifi cant results (87). 
2.4.3.2  Vasodilata? on
Reperfusion causes vasoconstriction and infl ammation further increases it by damaging the 
endothelium. Additionally, CNIs cause vasoconstriction. Calcium channel blockers, endothelin 
receptor antagonists and adenosine antagonists have all been proposed to be useful in preventing 
DGF (87). Calcium channel blockers somewhat decrease the incidence of DGF and result in 
signifi cantly better long-term kidney function that is independent of blood pressure lowering 
eff ects (89, 176, 177). Th e other drugs have so far only been used in experimental models of 
transplantation. 
2.5  Long-term kidney graŌ  funcƟ on
Kidney function at 1-year aft er transplantation is an independent predictor of long-term outcome 
and correlates with graft  failure and death with a functioning graft  (125, 178). Th is is probably 
mostly due to increased cardiovascular disease, as in kidney transplant patients graft  dysfunction 
is an independent risk factor for cardiovascular disease (179). All kinds of proteinuria (micro- or 
macro-proteinuria) occurring at any level or time aft er transplantation have a negative impact on 
graft  survival (180). In summary, 1-year kidney function is an important prognostic factor for 
long-term kidney function. 
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2.6  Acute kidney injury aŌ er liver transplantaƟ on
Kidney injury is an important and major complication in patients with advanced liver disease; 
approximately one in fi ve patients hospitalized with decompensated cirrhosis will develop renal 
failure (181, 182). In most cases this is caused by prerenal kidney injury resulting from infection, 
hypovolemia or hemorrhage and in 70% of cases it can be treated by volume expansion (182). 
Hepatorenal syndrome is a liver-disease related kidney injury resulting from complex changes in 
vasodilatation and vasoconstriction in systemic and renal circulation. It aff ects 18% of patients 
with advanced cirrhosis at one year and 39% at fi ve years (183). Prognosis of hepatorenal 
syndrome is poor: at best median survival time is six to seven months (184). 
Liver transplant recipients are at signifi cant risk for pre- and posttransplant AKI. Th e reported 
prevalence varies widely, from 8% to 78%, with 8% to 17% of patients needing renal replacement 
therapy (RRT) (185–187). Th e etiology of kidney injury is multifactorial, resulting from 
acute and chronic liver failure and factors related to transplant surgery and medication. Th e 
predominant risk factors for AKI are hepatorenal syndrome, perioperative hypotension, large 
volume transfusion, extended cross clamping time, use of CNI, nephrotoxic antibiotics and 
contrast media, infection, hypertension, diabetes and pre-existing chronic kidney disease (CKD) 
(186–189). Pre-existing CKD and pre- and posttransplant AKI associate with poorer outcomes 
aft er liver transplantation. Hence, a combined kidney–liver transplantation and individually 
designed immunosuppression would lead to better results among these patients (190). However, 
nowadays it is not possible before liver transplantation to identify patients who are going 
to develop posttransplant AKI or which patients on pretransplant RRT would benefi t from a 
combined kidney–liver transplantation. 
Liver transplant patients are also at increased risk for developing CKD aft er liver transplantation 
mainly due to CNI therapy, hypertension, diabetes and chronic hepatitis C infection (191). 
At present, the assessment of renal function is based on measuring urine output, serum/plasma 
creatinine and cystatin C levels, or using RIFLE, AKIN or the KDIGO Guideline for AKI 
classifi cations. As previously stated, creatinine is not a good marker of kidney injury in an acute 
unstable setting. Better markers for identifying patients at risk of AKI, and especially irreversible 
AKI resulting in permanent need for RRT, are needed.
 
2.7  Measuring kidney funcƟ on
2.7.1  Crea? nine
Creatine is broken down to phosphocreatinine in skeletal muscle and consequently non-
enzymatically to creatinine in the liver. In most people, muscle mass turnover is relatively 
constant and thus serum/plasma creatinine is relatively constant. Th ere are several factors 
directly aff ecting serum creatinine levels (age, gender, diet, muscle mass, drugs, race, fl uid 
status and exercise) or aff ecting the analysis method (hyperglycemia, bilirubin, cimetidine and 
cephalosporines) (192, 193). Creatinine is freely fi ltered by the glomerulus and actively secreted 
by the tubules. Th e rate of secretion depends on blood creatinine concentration. Additionally, 
Review of the Literature
21
creatinine secretion accounts for only 10% to 40% of creatinine clearance that can mask decline 
in GFR (194). 
When the GFR declines, the creatinine concentration in the blood rises. However, serum 
creatinine is insensitive to GFR changes and serum creatinine only becomes abnormal aft er 50% 
of GFR is lost. Th is is due to increased extrarenal metabolism and secretion of creatinine by the 
tubules. Additionally, it takes up to 24 hours to reach a steady state (192, 195). 
Creatinine is especially poor in assessing kidney function in patients with end-stage liver disease. 
Th e serum creatinine concentration in these patients tends to be lower than expected, since 
the synthesis of creatinine is reduced in the liver, they usually have reduced muscle mass, they 
exercise less than healthy individuals and their intake of protein is usually reduced. Additionally, 
patients with liver disease oft en have edema, further diluting the creatinine concentration in the 
blood (196).
2.7.2  Glomerular fi ltra? on rate (GFR)
Th e normal GFR is >90mL/min. GFR varies greatly between individuals due to age, body size, 
gender and race, but it is mostly constant within each individual. However, age-related decline in 
GFR is 0.75-1 mL/min per year aft er mid-adulthood (between 30 and 40 years of age).
GFR cannot be measured directly; thus, a surrogate marker is needed. An ideal marker for GFR 
measurement would be produced at a constant rate/exogenous, freely fi ltered by the glomerulus, 
without tubular reabsorption or secretion, or extrarenal metabolism. Additionally, there should 
be available an accurate inexpensive assay. Inulin clearance is the gold standard for measuring 
GFR, but it is too diffi  cult and expensive for clinical work. In fact, measuring clearance for any 
substance is laborious, slow and inaccurate, as 24 hours of urine collection is needed. Hence, 
in the clinic the assessment of GFR relies on the estimation of creatinine clearance using 
mathematical equations, which try to overcome some of the limitations related to urine collection 
(197). All of the equations are susceptible to the limits in use of creatinine as a marker of kidney 
injury. Additionally, they have been developed for use in a stable CKD population and they have 
not been validated and should not be used in an acute setting, although they commonly are. 
Th e Cockroft -Gault, modifi cation of diet in renal disease (MDRD), and CKD-EPI equations 
are used in patients over 18 years. In pediatric patients, GFR is estimated using the Schwarzt 
equation (198–201). Th e Cockroft -Gault equation was the fi rst widely used estimation for GFR: 
GFR = [(140-age) x weight]/72 x serum creatinine. In females the result is 
multiplied by 0.85. 
Th is estimation is inaccurate, as it uses weight as an index of muscle mass. Additionally, it 
overestimates GFR at low values in patients with CKD.
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Th e MDRD equation is considered more accurate than the Cockroft -Gault equation as it 
normalizes the results to body surface area (202): 
GFR = 170 x serum creatinine-0.999 x age-0.176 x 0.762 for females and x 1.18 if the 
patient is black. 
Th is equation may underestimate GFR in CKD stage 1 (if kidney function is normal but there 
is other evidence of kidney disease) and overestimate it in CKD stages 4 and 5 (if GFR <30 ml/
min/1.73m2). Th e MDRD equation has been validated in adults with impaired kidney function 
(GFR<60ml/min).
Th e CKD-EPI equation is the newest equation for estimating GFR. It is considered more accurate 
than the MDRD equation as it has less bias in CKD stage 1. Th e National Kidney Foundation and 
KDIGO recommend using the CKD-EPI in estimating GFR (203).
GFR = 141 x min(cr/κ,1)α  x max(cr/κ,1)-1.209 x 0.993age
Cr=serum creatinine, min=minimum serum creatinine / κ or 1
max=maximum serum creatinine / κ or 1, α= -0.329 in females and –0.411 in 
males
κ= 0.7 in females and 0.9 in males
Th e Schwartz formula is used to estimate GFR in children:
GFR = (k x height)/serum creatinine. 
Th e coeffi  cient (k) is: 0.33 for low birth weight infant <1 year, 0.45 for normal birth 
weight infant <1 year, 0.55 for child or adolescent girl, 0.70 for adolescent boy.
2.7.3  Urine output
Urine output is an approximate measure of kidney function. Many drugs, fl uid status, and other 
circumstances such as surgery aff ect urine output. In AKI, urine output can be decreased, normal 
or increased depending on tubular injury and tubular urine concentration capacity (204). 
2.7.4  Urea
Urea is a small by-product of protein metabolism that is freely fi ltered by the glomerulus but 
also signifi cantly reabsorbed. Th e rate of renal clearance of urea is not constant and varies, for 
example due to fl uid status. Urea concentration in blood increases with a decrease in GFR. 
However, nutritional status, protein intake, fl uid volume, steroid administration, fever, trauma, 
liver disease and gastrointestinal bleeding aff ect its concentration (205). Th e blood urea nitrogen 
to creatinine ratio has been suggested to discriminate between prerenal azotemia and acute 
kidney injury, but recent fi ndings do not support this (206).
2.7.5  Cysta? n C 
Cystatin C is a 13kDa protein produced in all nucleated cells at a relatively constant rate. It is 
not bound to plasma proteins and thus is freely fi ltrated through the glomerulus and reabsorbed 
in the proximal tubulus. It is not secreted into urine, so its clearance cannot be determined 
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(207). Th e appearance of cystatin C in the urine is thus related to kidney injury and cystatin 
C concentration correlates with GFR (208). However, there are some shortcomings concerning 
the use of cystatin C in the diagnosis of kidney injury: albuminuria may inhibit reabsorption 
of cystatin C by its receptor megalin and hence increase its concentration in urine (209, 210). 
Serum cystatin C concentration is aff ected by hypertriglyceridemia, diabetes, infl ammation, 
hyperthyroidism and steroid use (207, 211, 212).
Overall, cystatin C is not the perfect biomarker for kidney injury but, as Shlipak et al. concluded 
in a recent meta-analysis, measuring serum cystatin C alone or in combination with creatinine 
adds value when evaluating the association between GFR and the risk of ESRD or death (213). 
Th erefore, measuring serum cystatin C has been included in the KDIGO CKD guidelines. 
In a recent study of a panel of plasma and urine biomarkers, plasma cystatin C was found to 
moderately predict AKI (214).
2.8  Neutrophil gelaƟ nase-associated lipocalin
Neutrophil gelatinase-associated lipocalin (NGAL) is a 22–25kDa iron carrier protein. NGAL 
was fi rst identifi ed in human neutrophils bound with matrix metalloproteinase-9 (215, 216). 
Later, an iron binding siderophore, enterochelin, was also identifi ed as a ligand for NGAL (217, 
218). 
NGAL is a part of the lipocalin protein family. Th e lipocalins are secreted or cytosolic proteins 
that bind and transport several low molecular weight proteins such as retinoids, prostaglandins, 
iron, fatty acids, steroids and arachidonic acid (217, 219, 220). Th e ligand-binding pocket of 
NGAL is much larger and lined with more polar and positively charged amino acid residues than 
in other lipocalins. 
NGAL binds siderophores, a diverse group of small iron binding chemicals produced in bacteria, 
fungi, and plants (218, 221). NGAL associated with siderophore and iron (=holo-NGAL) enters 
the cell via an endocytic multiprotein megalin-cupulin receptor.  Another transmembrane 
receptor, 24p3R, has also been proposed to transport NGAL (222, 223). Aft er entering the cell, 
NGAL traffi  cs to endosomes and releases iron, resulting in the regulation of iron responsive genes 
coding, for example, ferritin and transferrin receptors (223, 224). By increasing intracellular iron 
uptake, NGAL plays a part in mesenchymal-epithelial transformation (225). NGAL without a 
siderophore-iron complex (apo-NGAL) can scavenge iron, for example from bacterial cells, and 
exit via the endosomal-recycling pathway (223) resulting in cell apoptosis, inhibition of bacterial 
growth and erythropoiesis (217, 223, 226). 
NGAL also acts as a growth factor, independent of ligands, by activating an extracellular signal 
regulated kinase and inducing promigratory and probranching eff ects (225). Hence, NGAL may 
protect tubular cells from ischemic injury (15, 221). However, knowledge of these non-iron 
related actions is still limited.
NGAL is constantly produced at low levels in neutrophils, adipocytes, and by stimulated, 
growing, dysplastic or involuting epithelial cells in various tissues in the skin, as well as 
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respiratory, gastro-intestinal and urinary tracts. Th at is, tissues that are constantly exposed to 
the external environment and thus bacteria (227–229). In healthy individuals, serum NGAL 
concentration in humans is approximately 20ng/mL (230). NGAL expression is induced by 
IL-1β, lipopolysaccharide, basic fi broblast growth factor, prostaglandin F2α, phorbol esther, 
dexamethasone, retinoic acid, serum and hypoxia, at the very least (15, 231). Elevated levels of 
NGAL have been reported in bacterial infections consistent with the bacteriostatic function of 
NGAL. Th e importance of this function has also been shown in vivo: NGAL defi cient mice are 
more susceptible to bacterial infections and sepsis (226, 232–234). Elevated NGAL levels are 
also found in various systemic settings without bacterial infection, such as in the acute phase 
response, renal tubular injury, infl ammation of the intestine, skin or airway, and cancer (14, 15, 
221, 224, 229, 231, 234–239). 
NGAL is freely fi ltered by the glomerulus due to its small size and positive charge. Th e kidney 
processes about 3.4–4mg of NGAL per day. Proximal tubule cells express a megalin receptor for 
NGAL uptake and NGAL is endocytosed and degraded to 14kDa fragments in lysosomes and 
the iron is recycled. Normal urine NGAL concentration is about 20ng/mL and it is derived from 
neutrophils, distal nephron cells mainly collecting ducts, and serum NGAL that has escaped the 
reabsorption in proximal tubulus (1/200 molecules) (230, 240). 
2.8.1  NGAL in kidney injury
Increased NGAL levels have been reported in acute kidney injury caused by ischemia 
(surgery, sepsis, hypovolemia, heart failure), nephrotoxins (antibiotics, cisplatin, non-steroidal 
anti-infl ammatory drugs, radiocontrast, hemoglobinuria), various chronic kidney disease 
(IgA nephropathy, membranous nephropathy, polycystic kidney disease), and in kidney 
transplantation predicting DGF and AR (11–50, 228, 237). Th e expression of NGAL increases 
rapidly–1000-fold in humans and rodents–in response to renal tubular injury (237). 
Kidney injury aft er cardiopulmonary bypass surgery, intravenous contrast administration and 
neonatal sepsis are examples of clinical situations where the actual timing of the damage can 
be determined. Using these settings, many studies have found that NGAL can be detected in 
the urine and blood within three hours aft er the original injury (14, 241–243). Th e amount of 
NGAL synthetized in the kidney is directly proportional to the size of the injury (244). Th is 
has also been shown in clinical situations: urine NGAL (uNGAL) and serum NGAL (sNGAL) 
concentrations are proportional to the recovery from DGF, uNGAL concentration is twice as 
high in bilateral vs. unilateral ureter obstruction, and NGAL concentration correlates with the 
AKIN or RIFLE kidney injury grade (19, 22, 25, 245–248). 
NGAL has been shown to predict AKI in several clinical settings. Firstly, serum and urine 
NGAL were shown to be independent predictors of AKI, morbidity and mortality in children 
undergoing cardiopulmonary bypass surgery (241). Serum and urine NGAL levels dramatically 
elevated between one to two hours aft er cardio-pulmonary bypass surgery in patients who later 
developed AKI, diagnosed by more than 50% rise in serum creatinine a few days later (14, 241, 
249). Th is has also been shown in adults, albeit with less predictive power (11–13, 250–252). 
NGAL has been shown to predict contrast induced nephropathy within two to four hours aft er 
contrast (21, 242, 253). In critically ill intensive care unit (ICU) patients NGAL is associated 
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with AKI development (254, 255). In children, an increase in urine NGAL was associated with 
worsening RIFLE category (256). Makris et al. found that NGAL predicts AKI in critically ill 
multiple trauma patients (20) and Nickolas et al. also found that NGAL predicts AKI in patients 
arriving in an emergency room irrespective of diagnosis (18). In CKD, serum and urine NGAL 
refl ect the severity and progression of kidney disease (257–259).
CKD patients have a chronic infl ammatory state due to frequent infections, uremia, an increase 
in proinfl ammatory cytokines, widespread atherosclerosis, and dialysis. In these patients, the iron 
metabolism is off  balance (260, 261). Bolignano et al. suggested that elevated NGAL in dialysis 
patients is due to the involvement of NGAL in iron equilibrium, and serum NGAL could be used 
in the assessment of iron defi ciency in ESRD patients (260, 261). NGAL might contribute to the 
progression of CKD as a result of proinfl ammatory properties or iron dependent functions (262). 
Recently, Liu et al. found that urine NGAL in CKD patients independently associates with future 
ischemic events (263).
NGAL has been found to predict kidney function aft er heart, heart–lung and liver transplantation 
(39–42, 264–266). Aft er kidney transplantation, serum/plasma NGAL has been shown to predict 
DGF (22–38). 
NGAL is important in the diagnosis of kidney disease as it directly measures tissue damage in a 
dose-response fashion. NGAL expression is rapid and reversible, which means that NGAL can 
also be used to monitor the eff ect of treatment. 
2.8.2  NGAL detec? on methods
Immunoblotting is the gold standard in NGAL analyses. However, it is time consuming, 
laborious and prone to human error and is not well suited for clinical work. Nowadays, various 
commercially available detection methods and kits exist for NGAL analyses. Enzyme-linked 
immunosorbent assay (ELISA) methods can be used to analyze NGAL in serum, plasma and 
urine. Th e point-of-care (POC) method can be used to analyze NGAL in whole blood and 
plasma, and the ARCHITECT® method to analyze NGAL in urine.
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3.  AIMS OF THE STUDY
Th e aim of the study is to prospectively analyze the role of serum and urine NGAL in kidney 
transplant donors and recipients and liver transplant recipients. Th e specifi c aims are to examine:
1. Whether urine and serum NGAL levels in deceased kidney donors predict DGF and 
prolonged DGF (I)
2. How serial urine NGAL concentrations change over time aft er kidney transplantation and 
whether recipient urine NGAL predicts DGF and prolonged DGF (II)
3. How serial serum NGAL concentrations change over time aft er kidney transplantation and 
whether recipient serum NGAL predicts DGF and prolonged DGF (III)
4. To compare the ELISA and POC methods in serum NGAL analyses (III)
5. Whether plasma NGAL concentration predicts AKI or need for renal replacement therapy 
aft er liver transplantation (IV)
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4.  PATIENTS AND METHODS
Th e study was performed at Helsinki University Hospital, which is the only transplant center 
in Finland providing a nationwide organ transplant service. Th e local ethics committee and the 
Department of Surgery approved the study protocol. Th e study was performed in accordance 
with the Helsinki 1975 declaration.
4.1  Study design
Th e study designs are summarized in Table 1.
Table 1. Summary of studies I–IV
PaƟ ents eGFR Sample material
Method
Sample Ɵ ming
Study I Kidney donors
N=99
MDR Urine and serum
ELISA
Urine
At the beginning of donor surgery
Serum
At donor hospital simultaneously 
with serum sample for HLA typing
Study II Kidney recipients
N=176
CockroŌ -Gault Urine
ARCHITECT®
At arrival to the TX unit
The 1st morning aŌ er TX
On day 3
On day 7
On day 14
Study III Kidney recipients
N=176
CockroŌ -Gault Serum
Elisa, POC
At arrival to the TX unit
The 1st morning aŌ er TX
On day 14
Study IV Liver recipients
N=203
MDRD Plasma
POC
On the day of TX or shortly before
eGFR= estimated glomerular fi ltration rate, TX = transplantation, POC = point-of-care
4.2  PaƟ ents
For the kidney studies we prospectively enrolled 100 consecutive, deceased, heart-beating 
donors, and their adult kidney recipients, between August 2007 and December 2008. 
Altogether, 196 donated kidneys were transplanted. Six kidneys were transplanted to pediatric 
recipients, nine kidneys were shipped to other Scandinavian transplant centers according to the 
Scandiatransplant exchange obligation rules, and two kidneys were transplanted for patients 
needing a combined kidney–liver or a kidney–lung transplantation. Th e remaining 179 kidney 
recipients were eligible for the study. Th ree patients refused consent. Hence, 99 donors and 176 
kidney recipients were included in this study. Written informed consent was obtained from the 
recipients before enrolment. Th e primary outcome variable was the onset of graft  function aft er 
kidney transplantation. Th e follow-up time was one year.
For the liver study, we included 211 adult liver transplant recipients between 2005 and 2010. 
Patients receiving combined liver–kidney transplantations (n=7) were excluded. No other 
exclusion criteria were used. Th e remaining 203 patients were included in the study, although 
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one did not have an adequate sample for NGAL analyses. Th e follow-up time was 90 days aft er 
transplantation. 
Aft er transplantation, the immediate post-operative care took place at the Helsinki University 
Hospital. Th e patients’ clinical data were obtained from their hospital records, the Finnish 
Kidney Transplant Registry and the Finnish Liver Transplant Registry databases.
4.2.1  Kidney donors
Th e donors were treated in their local hospitals around Finland. Th is study did not aff ect their 
treatment in any way. Th e clinical history data of the donors were obtained from their hospital 
records. Th e following parameters were collected: age, gender, history of hypertension, need for 
cardiopulmonary resuscitation, need for intracranial surgery, use of vasopressor support, use 
of antidiuretic hormone (ADH), plasma creatinine, length of hospital stay before brain death 
diagnosis, cause of death and multiorgan or kidney-only donation. None of the donors had 
diabetes mellitus. Th e donors were stratifi ed to normal criteria donors and ECDs according 
to Port et al. (72). Th e donors were regarded as ECD if they were older than 60, or older than 
50 with at least two of the following: plasma creatinine more than 133μmol/L (1.5mg/dL), 
cerebrovascular accident as cause of death, or a history of hypertension.
According to the valid protocol, intravenous steroids were given to all donors before the organ 
retrieval operation. Intravenous mannitol was administrated before in situ perfusion. A kidney 
biopsy was taken before the initiation of in situ perfusion. Th e biopsy was assessed for histology 
according to the Banff  97 criteria (267) and the chronic allograft  damage index (CADI) (268). 
University of Wisconsin solution was used for the in situ perfusion and cold storage preservation 
of the kidneys. 
4.2.2  Kidney transplant recipients
For the kidney transplant recipients, data on the following parameters were collected: age, gender, 
underlying kidney disease, number of previous kidney transplants, mode of dialysis, time on 
dialysis before transplantation, the amount of daily urine output at arrival to the transplant unit 
and aft er transplantation, plasma creatinine level upon arrival to the transplant unit and daily 
aft er transplantation, and estimated GFR (eGFR) at three weeks, three months and one year aft er 
transplantation.
Th e study did not aff ect the recipients’ treatment in any way; all the patients were treated according 
to the current protocol with triple immunosuppression consisting of CNI (cyclosporine A or 
tacrolimus), mycophenolate mofetil and steroids. CNI was started orally before transplantation, 
and continued aft er transplantation (target levels 200 to 250ng/mL for cyclosporine and 6 to 12 
ng/mL for tacrolimus) for two weeks and the target levels were subsequently tapered according to 
treatment protocol. Th e target dose for mycophenolate mofetil was 1 g twice a day for patients on 
cyclosporine and 500 mg twice a day for patients on tacrolimus. Induction immunosuppression 
with IL-2R was given to 28 (basiliximab, n=19, daclizumab, n=9) highly sensitized recipients or 
recipients for whom steroids needed to be minimized.
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4.2.3  Liver transplant recipients
For the liver transplant recipients, data on the following parameters were collected: age; 
gender; creatinine and eGFR at listing and transplantation day; pretransplant need for RRT; 
transplantation day MELD (model for end-stage liver disease) score; bilirubin, albumin and 
INR; amount of total bleeding; anhepatic time; day-1 lactate concentration and the highest value 
of bilirubin; alanine aminotransferase and INR; and the lowest eGFR value during the fi rst week 
aft er transplantation. Th e three highest trough levels of cyclosporine or tacrolimus during the 
fi rst week aft er transplantation were collected. 
Th e study did not aff ect the treatment of the liver transplant recipients in any way. Th e patients 
received standard CNI based immunosuppression (cyclosporine n=140, tacrolimus n=63), with 
mycophenolate mofetil or azathioprine, and steroids. Th e target level of cyclosporine was 200 
to 250ng/mL for the fi rst month and 150 to 200ng/mL aft er that, and tacrolimus 5 to 15ng/
mL for the fi rst three months. Th e patients were considered to have excessive exposure to CNI 
with trough levels of >300ng/mL for cyclosporine and >20ng/mL for tacrolimus. During the 
fi rst month 13 patients were switched from cyclosporine to tacrolimus due to AR, which was 
histologically confi rmed and treated with intravenous methylprednisolone. As part of a trial, 30 
patients received interleukin-2 receptor antagonist induction therapy with reduced dose of CNI 
or delayed initiation of CNI at day 5 aft er transplantation. 
4.3  Defi niƟ on of DGF and prolonged DGF
In studies I and II, DGF was defi ned according to Halloran et al. (269): urine output less than 
1L/24 hours for more than two days, or plasma creatinine concentration >500μmol/L throughout 
the fi rst week, or more than one dialysis session needed during the fi rst week. As the need for 
dialysis during the fi rst week aft er transplantation is the most commonly used defi nition for 
DGF, we used it along with the Halloran defi nition in Study II and as the main defi nition of DGF 
in Study III. To assess the duration of DGF we divided the transplantations in all three studies 
into three groups: early graft  function (EGF), short DGF lasting less than 14 days, and prolonged 
DGF lasting 14 days or longer. 
4.4  Assessment of kidney funcƟ on and defi niƟ on of AKI in 
liver transplant paƟ ents
Th e amount of daily urine output was measured and recorded from the donors before the organ 
retrieval operation and from the recipients before transplantation and daily aft er transplantation. 
Plasma creatinine was measured in the hospital laboratory using a photometric, enzymatic and 
accredited assay. Estimated GFR for recipients and adult donors was calculated using the MDRD 
equation in studies I and IV and Cockroft -Gault equation in studies II and III. For three pediatric 
donors, the eGFR was calculated using the Schwartz formula.  
Plasma cystatin C was measured in the hospital laboratory using a photometric, immunochemical 
method from the liver transplant recipients and was used to calculate eGFR by the cystatin 
C-based chronic kidney disease epidemiology collaboration equation (CKD-EPI). Pre-transplant 
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cystatin C measurements were available in 174 (86%) patients and 3-month measurements in 
151 (77%). 
In liver transplant recipients, AKI was determined as one of the following: (1) >100% increase 
in transplant day creatinine, (2) >50% decrease in eGFR from transplant day to an end eGFR 
of <60mL/min at three months, or (3) a rise in creatinine to an end creatinine of >350μmol/L 
in patients with pretransplant eGFR <60mL/min. Molecular adsorbent recirculating system 
(MARS) therapy always included hemodialysis and in Study IV MARS treatment is considered 
as RRT.
4.5  Assessment of liver funcƟ on
Th e MELD score is a chronic liver disease severity scoring system that predicts 3-month survival. 
It is calculated from plasma creatinine, INR, and bilirubin concentration. Th e highest values of 
INR, bilirubin and alanine aminotransferase during the fi rst week aft er transplantation were 
used to determine liver graft  dysfunction aft er transplantation. 
4.6  NGAL sample collecƟ on
4.6.1  Donors
Serum samples were collected from the donors in their local hospitals simultaneously with the 
blood sample for HLA typing. Serum samples were available for NGAL analyses from 95 donors. 
In four cases sNGAL could not be determined due to inadequate (n=2) or incorrectly processed/
stored (n=2) sampling. 
Urine samples were taken at the beginning of donor surgery by the transplant team. Donor 
uNGAL levels could not be determined in four cases because of inadequate (n=1) or incorrectly 
processed/stored (n=3) samples. 
4.6.2  Kidney recipients
Th e kidney recipient serum and urine samples were collected on arrival to the transplant unit 
before transplantation and serum samples in the mornings of days 1 and 14 aft er transplantation 
and urine samples in the morning of days 1, 3, 7 and 14 aft er transplantation. Th e following 
number of serum samples were obtained: day 0 n=141, day 1 n=170, day 14 n=166. Due to 
oliguria or anuria some of the recipients were not able to give a urine sample. We obtained the 
following number of urine samples at each time point: day 0 n=70, day 1 n= 134, day 3 n=139, 
day 7 n=151, day 14 n=154.
4.6.3  Liver recipients
Th e plasma samples from liver transplant recipients were collected on the day of transplantation 
(n=158), on arrival to the transplant unit, or a few days before (n=45) in cases of acute liver 
failure or at onset of dialysis in patients receiving pretransplant RRT.
Patients and Methods
31
4.7  NGAL analyses
All serum and urine samples were immediately centrifuged at 2500RPM, 4°C for 10 minutes and 
the plasma samples at 3000RPM. Th e supernatant was immediately collected, divided into tubes, 
frozen and stored at -70°C. No additives were used. For analysis, the urine and serum samples 
were thawed at room temperature. Repeated freeze–thaw cycles were avoided.
4.7.1  Serum and plasma NGAL
4.7.1.1  ELISA
In studies I and III the sNGAL assays were performed using a commercial enzyme-linked 
immunosorbent assay (ELISA) kit (BioPorto Diagnostics A/S, Gentoft e, Denmark) as 
recommended by the manufacturer. Th e intra- and inter-assay precision were good; the 
median coeffi  cient of variation was <10% for both. Th e samples were diluted to 1:50 for optimal 
measuring feature. Th e screening frequency was set to 450nm and the reference frequency to 
620nm. With this validated method, the measuring range was 10 to 1000ng/ml. Out of range 
values were re-analyzed with an individualized dilution. Th e measurements were performed in 
duplicate and blinded to clinical information.
4.7.1.2  Point-of-care
In studies III and IV the NGAL levels were analyzed using the POC fl uorescence immunoassay 
NGAL kit and device (Triage®, Biosite, San Diego, CA, USA) as recommended by the manufacturer. 
Th e specimen can be used as such; no preliminary dilutions are needed. Th e specimen was added 
to the sample port on the test device where it reacts with fl uorescent antibody conjugates. Th e 
test device was then inserted to the measuring device, which automatically measures the amount 
of fl uorescence and calculates the NGAL concentration. Th e measurements were performed in 
duplicate and blinded to sample sources and clinical outcome.
4.7.2  Urine NGAL
In studies I and II the uNGAL assays were performed using a two-step chemiluminescent 
microparticle immunoassay on a standardized clinical platform (ARCHITECT® analyzer, Abbott 
Diagnostics, Abbott Park, IL, USA) as recommended by the manufacturer. Prior to setting up 
the system, we performed a 5-day precision study where three levels of controls were assayed in 
replicates of two on each run (total n=20 for each control). Th is showed good precision for the 
urine NGAL assay (median coeffi  cient of variation <10%). Th e samples were diluted to 1:10. Th e 
sample was combined with anti-NGAL coated paramagnetic microparticles, a labeled conjugate 
was added, and the resulting chemiluminescent reaction was measured. Th e measuring range 
was 0-1500ng/ml and the machine further automatically diluted specimens for NGAL values 
exceeding 1500ng/ml. Th e measurements were performed in duplicate and blinded to sample 
sources and clinical outcome.
4.8  StaƟ sƟ cal analyses
Th e SPSS soft ware, version 20.0 (SPSS Inc., Chicago, IL, USA), was used for statistical analyses. 
All analyzed variables were tested for distribution. We used the T-test, ANOVA and Pearson 
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correlation for samples with normal distribution. Samples with skewed distribution were 
analyzed with the Mann-Whitney U, Kruskal-Wallis and Spearman correlation tests. Chi-square 
and Fisher’s exact tests were employed in the analyses of contingency tables. Forward, conditional 
multilogistic regression analyses were used to assess DGF, prolonged DGF and AKI predictors 
in donors and kidney and liver transplant recipients. Factors signifi cantly diff ering between the 
DGF and EGF groups in the univariate analyses, and also the other clinically relevant factors in 
this respect, were included in the multivariate analyses. Th ese factors in the multivariate analyses 
consisted of categorical variables and the covariates of continuous variables. A receiver operating 
characteristic (ROC) analysis was performed to assess the potential of NGAL to predict DGF, 
prolonged DGF and AKI aft er liver transplantation. A p-value <0.05 was considered signifi cant.
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5.  RESULTS
5.1  Kidney donors and recipients, and DGF
Studies I, II and III included 99 deceased donors and 176 adult, kidney transplant recipients. 
DGF was seen in 70 (39.8%) transplantations. Th e graft s with DGF started to function a mean 
12 days aft er transplantation (range 3 to 38, SD 7). Th e EGF graft s started to function a mean 
1.3 days aft er transplantation. Th e donor, recipient and transplantation characteristics are shown 
in tables 2, 3, and 4. Th e data is shown for all transplantations and stratifi ed for EGF and DGF 
groups using the Halloran et al. (114) criteria. 
Table 2. Clinical characteristics in all donors and diff erences in donor characteristics between early 
and delayed graft  function groups. P-value indicates the diff erence between the EGF and DGF groups.
N
All donors
99
EGF
106
DGF
70
p-value
Mean age, years 51.8 (9–75) 49.1 (9–75) 55.8 (9–75) 0.002
Gender
Male 56 (56.6%) 62 (58.5%) 42 (60.0%) NS
Cause of death
Cerebrovascular accident
TraumaƟ c brain injury
74 (74.7%)
25 (25.3%)
75 (70.8%)
33 (31.2%)
57 (81.4%)
13 (18.6%)
NS
Mean plasma creaƟ nine, μmol/L 62 (28–143) 63 (21.0) 64 (17.4) NS
Mean eGFR, mL/min 122 (60–263) 124 (39.2) 115 (35.0) NS
History of hypertension 27 (27.3%) 26 (24.5%) 24 (34.3%) NS
Expanded criteria donors 38 (38.4) 33 (31.1%) 36 (51.4%) 0.007
Need for cardiopulmonary resuscitaƟ on 21 (21.2%) 25 (23.6%) 10 (14.3%) NS
Ante mortem intracranial surgery 30 (30.3%) 19 (17.9%) 22 (31.4%) NS
Use of inotropes 87 (87.9%) 63 (59.4%) 62 (88.6%) NS
Use of ADH 60 (60.6%) 50 (47.2%) 38 (54.3%) NS
MulƟ organ donor 56 (56.6%) 39 (36.8%) 38 (54.3%) NS
Days in hospital before brain death 1.9 (1–14) 2.0 (2.5) 1.6 (1.3) NS
Mean cold ischemia Ɵ me, hours (SD) 21.8 (3.5) 21.3 (3.7) 22.9 (3.6) 0.007
eGFR=estimated glomerular fi ltration rate, ADH= anti diuretic hormone, EGF=early graft  function, 
DGF=delayed graft  function.
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Table 3. Clinical characteristics in all kidney recipients and diff erences between patients with early 
and delayed graft  function. P-value indicates the diff erence between the EGF and DGF groups.
All Recipients EGF (n=106) DGF (n=70) p-value
N 176 106 (60.2%) 70 (39.8%)
Mean age, years 52.0 (19–76) 50.5 (20–70) 54.1 (19–76) NS
Gender
Female
Male
66 (37.5%)
110 (62.5%)
45 (42.5%)
61 (57.5%)
21 (29.6%)
49 (69.4%)
NS
Kidney transplant number
1st transplantaƟ on
2nd transplantaƟ on
3rd transplantaƟ on
161 (91.5%)
13 (7.4%)
2 (1.1%)
99 (93.4%)
6 (5.7%)
1 (0.9%)
62 (88.6%)
7 (10.0%)
1 (1.4%)
NS
Underlying kidney disease
PolycysƟ c disease
GlomerulonephriƟ s
Diabetes mellitus 
Other
42 (23.8%)
35 (19.9%)
48 (27.3%)
51 (30.0%)
26 (24.5%)
21 (19.8%)
29 (27.4%)
30 (28.3%)
16 (22.9%)
14 (20.0%)
19 (27.1%)
21 (30.0%)
NS
Mode of dialysis 
Hemodialysis
Peritoneal dialysis
114 (64.8%)
62 (35.2%)
62 (58.5%)
44 (41.5%)
52 (74.3%)
18 (25.7%)
0.032
Mean Ɵ me on dialysis, days 850 (73–4263) 770 (73–4263) 975 (187–3361) 0.007
EGF=early graft  function, DGF=delayed graft  function
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Table 4. Transplantation characteristics in all kidney transplantations and diff erences between 
patients with early and delayed graft  function. P-value indicates the diff erence between the EGF and 
DGF groups.
All Recipients EGF (n=106) DGF (n=70) p-value
IniƟ al calcineurin inhibitor
Tacrolimus
Cyclosporine A
41 (23.3%)
135 (76.7%)
24 (22.6%)
82 (77.4%)
17 (24.3%)
53 (75.7%)
NS
Mean plasma creaƟ nine, μmol/L
Day 1
Day 3
Day 7
3 weeks
3 months
1 year
531 (112–1383)
407 (60–1253)
270 (53–925)
153 (52–530)
124 (56–525)
116 (43–312)
445 (112–1353)
250 (60–805)
141 (53–333)
120 (52–280)
110 (56–200)
109 (43–312)
664 (274–1383)
644 (298–1253)
458 (119–925)
206 (67–530)
148 (59–515)
128 (73–276)
<0.001
<0.001
<0.001
<0.001
<0.001
0.002
Mean eGFR, mL/min
3 weeks
3 months
1 year
57.4 (15–148)
65.5 (17–175)
72.1 (21–153)
64.2 (25–148)
69.7 (27–175)
74.8 (21–153)
46.4 (15–99)
58.9 (17–113)
67.7 (29–132)
<0.001
0.003
0.05
Mean urine output, mL
Day 1
Day 3
Day 7
Day 14
1756 (0–9280)
1729 (0–5970)
1960 (0–4630)
2339 (0–4720)
2544 (100–9280)
2406 (150–5970)
2412 (1500–4630)
2661 (1070–4720)
574 (0–2350)
713 (0–2880)
1274 (0–3530)
1888 (0–4710)
<0.001
<0.001
<0.001
<0.001
Acute rejecƟ on 10 (5.7%) 4 (3.8%) 6 (8.6%) NS
Mean Ɵ me to rejecƟ on, days 16.8 (7–49) 8.7 (7–11) 20.8 (14–49) NS
1-year graŌ  survival 95.5% 99.1% 90.0% 0.005
1-year paƟ ent survival 99.4% 100% 98.6% NS
EGF=early graft  function, DGF=delayed graft  function, eGFR=estimated glomerular fi ltration rate
In the DGF group, the donors were older and there were more ECDs compared to the EGF 
group. In the DGF group, the CIT was longer compared to the EGF group. Of the studied 
recipient characteristics there were more patients on maintenance hemodialysis (instead of 
peritoneal dialysis) and time spent on dialysis before transplantation was longer in the DGF 
group compared to the EGF group. Kidney function was better in the EGF group compared to 
the DGF group at all measured time points, including at one year aft er transplantation. Graft  
survival at one year was signifi cantly better in the EGF group compared to the DGF group. 
5.2  Prolonged DGF
Of the 70 DGF recipients, 26 had prolonged DGF lasting >14 days. Th e diff erences between the 
short and prolonged DGF groups are shown in Table 5. Th ere were no signifi cant diff erences 
in pretransplant or transplantation characteristics between these groups. Graft  survival and 
function were signifi cantly better in the short DGF group compared to the prolonged DGF 
group at one year aft er transplantation. 
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Table 5. Diff erences between the short and prolonged DGF groups
DGF<14 days DGF>14 days p-value
N 44 26
Mean recipient age, years (SD) 55.3 (11.9) 52.0 (15.4) NS
First transplantaƟ on 38 (86.4%) 24 (92.3%) NS
Mode of dialysis, hemodialysis 36 (81.8%) 19 (73.1%) NS
Mean Ɵ me on dialysis, days (SD) 993 (683.2) 929 (430.9) NS
Donor age, years (SD) 55.6 (12.1) 56.0 (SD 10.7) NS
Mean CIT, hours (SD) 22.7 (3.8) 23.3 (3.4) NS
ECD donor status 20 (45.5%) 16 (61.5%) NS
Day 1 creaƟ nine, μmol/L (SD) 648 (205.4) 676 (224.6) NS
Day 1 urine output, mL (SD) 618 (648.8) 392 (446.6) NS
1-year creaƟ nine, μmol/L (SD) 115 (33.4) 156 (47.3) 0.002
1-year eGFR, mL (SD) 72 (22.8) 56 (20.1) 0.009
1-year graŌ  survival 100% 73.1% <0.0001
1-year paƟ ent survival 100% 96.2% NS
DGF=delayed graft  function, CIT=cold ischemia time, ECD=expanded criteria donors, 
eGFR=estimated glomerular fi ltration rate
5.3  Donor kidney biopsies
All donors were biopsied before in situ perfusion of the kidneys. Histological evaluation was 
available from 97/99 biopsies. Normal histology was seen in 58/97 (59%) biopsies. Th e mean 
CADI score was 0.72 (range 0 to 5). Donor biopsies were mostly normal. Arterial changes in the 
form of intimal thickening, hyalinosis and global sclerosis were the most commonly observed 
fi ndings in the biopsies. Th e histological changes found in the donor biopsies are shown in 
Table 6.
Table 6. Donor biopsy fi ndings
Number of biopsies (%)
TubuliƟ s 0 (0%) 
InƟ mal arteriƟ s 0 (0%)
IntersƟ Ɵ al infl ammaƟ on 1 (1.0%)
GlomeruliƟ s 0 (0%)
IntersƟ Ɵ al fi brosis 5 (5.2%)
Tubular atrophy 6 (6.2%)
Presence of scleroƟ c glomeruli 30 (30.9%)
Mesangial matrix increase 1 (1.0%)
Global sclerosis 21 (21.6%)
InƟ mal thickening 25 (25.8%)
Arterial hyalinosis 23 (23.7%)
CADI score
 0–1
 ≥2
79
18
CADI=chronic allograft  damage index
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5.4  Donor NGAL
5.4.1  Donor uNGAL (I)
Th e mean donor uNGAL was 18 ng/ml (SD 26). Donor uNGAL correlated directly with plasma 
creatinine (r=0.37, p<0.0001) and inversely with eGFR (r=0.24, p=0.01). ADH treated donors 
had signifi cantly lower mean uNGAL levels (13ng/ml, SD 14) compared to non-ADH treated 
donors 26ng/ml, SD 37, p=0.045). Donor uNGAL did not correlate with age (r=0.12) and was 
not aff ected by the use of vasopressors, history of hypertension, length of hospital stay, need for 
cardiopulmonary resuscitation or intracranial surgery, gender, ECD or standard criteria donor 
status, or multiorgan or kidney-only donation.
Th ere were no signifi cant diff erences in mean donor uNGAL levels between the DGF (23ng/ml, 
SD33) and EGF (16ng/ml, SD20, p=0.058) groups. In cases with prolonged DGF, the mean donor 
uNGAL was signifi cantly higher (35ng/ml, SD49) compared to cases with short DGF (15ng/ml, 
SD14), or EGF (16ng/ml, SD20, p=0.002).
Th e donor uNGAL values were divided into High and Low according to a mean uNGAL 
concentration 18ng/ml. Th e characteristics in these groups are shown in Table 7. Th e High 
uNGAL group comprised 26 donors who donated 52 kidneys and the Low uNGAL group of 69 
donors donating 116 kidneys. Graft  survival was signifi cantly better in the Low uNGAL group 
(97.4%) compared to the High uNGAL group (90.3%, p=0.048) at one year.
Table 7. Diff erences between the transplantations stratifi ed according to low and high uNGAL 
concentration, using the mean concentration as a cut-off  value
Low uNGAL (<18 ng/mL)
Donors n=69
Kidneys n=116
High uNGAL (≥18 ng/mL)
Donors n=26
Kidneys n=52
p-value
Donor creaƟ nine μmol/L (SD) 59 (17.8) 71 (21.8) 0.006
Donor eGFR ml/min (SD) 122 (35.7) 105 (31.2) 0.039
CADI score
0–1
>2
61
8
17
9
0.010
Prolonged DGF (n=25)
Short DGF (n=41)
EGF (n=102)
13 (11.2%)
26 (22.4%)
77 (66.4%)
12 (23.1%)
15 (28.8%)
25 (48.1%)
0.028
1-year creaƟ nine μmol/L (SD) 117 (45.0) 114 (28.5) NS
1-year eGFR mL/min (SD) 59 (21.4) 57 (15.9) NS
1-year paƟ ent survival 100% 95.8% NS
1-year graŌ  survival 97.4% 90.3% 0.048
uNGAL=urine neutrophil gelatinase-associated lipocalin, eGFR=estimated glomerular fi ltration rate, 
CADI=chronic allograft  damage index, DGF=delayed graft  function, EGF=early graft  function
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5.4.2  Donor sNGAL (I)
Th e mean donor sNGAL was 212ng/ml (SD 145). Donor sNGAL directly correlated with donor 
uNGAL (r=0.40, p<0.0001). It also correlated directly with plasma creatinine (r=0.35, p=0.001) 
and inversely with eGFR (r=0.24, p=0.021). Donors treated with ADH had signifi cantly lower 
mean sNGAL levels (188ng/ml, SD 125) compared to non-ADH treated donors (249ng/
ml, SD 161, p=0.002). Donor sNGAL was not aff ected by the use of vasopressors, history of 
hypertension, length of hospital stay, need for cardiopulmonary resuscitation or intracranial 
surgery before brain death, gender, ECD or standard criteria donor status, and multiorgan or 
kidney-only donation. Donor sNGAL did not correlate with donor age (r=0.15).
Th ere were no signifi cant diff erences in mean donor sNGAL levels between the DGF (229ng/ml, 
SD 136) and EGF (206ng/ml, SD 150, p=NS) groups. Mean donor sNGAL concentration did not 
signifi cantly diff er between groups of prolonged DGF (220ng/ml, SD 142), short DGF (234ng/
ml, SD 135), or EGF (206ng/ml, SD 150, p=NS).
We divided the donor sNGAL values into High and Low according to the mean sNGAL 214ng/
ml. Th e characteristics of these groups are shown in Table 8. Th e High sNGAL group had 38 
donors who donated 69 kidneys and the Low uNGAL group had 57 donors donating 99 kidneys. 
Th e 1-year graft  survival rate was signifi cantly better in the Low sNGAL group (98.0%) compared 
to the High sNGAL group (91.4%, p=0.050).
Table 8. Diff erences between the transplantations stratifi ed according to low and high sNGAL 
concentration, using the mean concentration as a cut-off  value
Low sNGAL (<214 ng/mL)
Donors n=57
Kidneys n=99
High sNGAL (≥214 ng/mL)
Donors n=38
Kidneys n=69
p-value
Donor creaƟ nine μmol/L (SD) 57 (15.1) 70 (22.8) 0.021
Donor eGFR ml/min (SD) 124 (34.5) 108 (33.9) 0.033
CADI score
0–1
>2
46
11
30
8
NS
Prolonged DGF (n=25)
Short DGF (n=41)
EGF (n=102)
13 (13.1%)
19 (19.1%)
67 (67.8%)
12 (17.4%)
22 (31.9%)
35 (50.7%)
NS
1-year creaƟ nine μmol/L (SD) 115 (37.7) 117 (43.8) NS
1-year eGFR mL/min (SD) 60 (21.1) 57 (16.9) NS
1-year paƟ ent survival 99.0% 98.6% NS
1-year graŌ  survival 98.0% 91.4% 0.050
sNGAL=serum neutrophil gelatinase-associated lipocalin, eGFR=estimated glomerular fi ltration 
rate, CADI=chronic allograft  damage index, DGF=delayed graft  function, EGF=early graft  function.
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5.5  Kidney recipient NGAL
5.5.1  Kidney recipient uNGAL (II)
Th e mean uNGAL was high (1209ng/ml, SD 1120) in all patients before transplantation. It was 
not aff ected by recipient age, gender, underlying kidney disease, mode or length of dialysis, 
number of previous transplantations, pretransplant diuresis or plasma creatinine (data not 
shown).
Recipients with diuresis of more than 1L on day 1 had signifi cantly lower uNGAL levels (543ng/
ml, SD 642) compared to those with diuresis of less than 1L (887ng/ml, SD 613, p=0.008). Th e 
day-1 uNGAL was not aff ected by a decrease/increase in plasma creatinine from day 0 to day 1. 
Th e mean pretransplant uNGAL concentration was higher in the DGF group but this diff erence 
was not statistically signifi cant. Th e mean uNGAL levels decreased in both groups aft er 
transplantation, but the decrease was faster and the mean levels were signifi cantly lower in the 
EGF group compared to the DGF group at all measured time points (Figure 2). In the prolonged 
DGF group, uNGAL levels remained high at all measured time points (Figure 2).
Figure 2. Th e mean uNGAL concentrations divided according to EGF and DGF and early vs. 
prolonged onset of function at all measured time points. 
5.5.2  Serum NGAL analysis (II)
Both Elisa and POC methods were used to analyze pretransplant serum samples from 132 kidney 
recipients and day-1 samples from 128 recipients. Using the Elisa method, the mean sNGAL 
was 506ng/ml (SD 189). Using the POC method, the mean sNGAL concentration was 536ng/
ml (SD 238). Figure 3 shows the corresponding Elisa and POC measured sNGAL values and the 
corresponding mean sNGAL levels with SEM. Th e correlation between Elisa and POC measured 
sNGAL levels was 0.89, p<0.0001. As the POC method is more practical and the correlation with 
Elisa was good, sNGAL values measured using the POC method are used for the clinical analyses 
in this study.
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Figure 3. Th e correlation of sNGAL values measured using the Elisa and the POC method
5.5.3  Kidney recipient sNGAL (III)
Th e mean pretransplant sNGAL was 678ng/ml. It was signifi cantly lower (356ng/ml, SD 168.1) 
in recipients with residual diuresis >1000ml from their native kidneys compared to those with 
residual diuresis <1000ml (593ng/ml, SD 186, p<0.0001). Pretransplant sNGAL was not aff ected 
by recipient age, gender, underlying kidney disease, mode or length of dialysis, number of 
previous transplantations, or plasma creatinine (data not shown).
Th e day aft er transplantation, recipients with decreasing plasma creatinine had signifi cantly 
lower sNGAL level (382ng/ml, SD 196) compared to those with no change/increase in plasma 
creatinine on day 1 (547ng/ml, SD 187, p<0.0001). Recipients with diuresis of more than 1L 
on day 1 had signifi cantly lower sNGAL levels (356ng/ml, SD 168) compared to those with 
diuresis of less than 1L (593ng/ml, SD 186, p<0.0001). Th ere were no statistically signifi cant 
diff erences in mean pretransplant sNGAL concentrations between the EGF and DGF groups. 
Aft er transplantation, the mean sNGAL levels decreased in both groups but more rapidly in the 
EGF group compared to the DGF group (Figure 4). In the prolonged DGF group sNGAL levels 
remained high at all measured time points (Figure 4).
Figure 4. Th e mean sNGAL concentrations divided according to EGF and DGF and early vs. 
prolonged onset of function at all measured time points. 
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5.6  NGAL in the predicƟ on of graŌ  funcƟ on onset (II, III)
5.6.1  DGF
ROC analyses were performed to assess the potential of donor and recipient uNGAL and 
sNGAL to predict DGF (Figure 5). Recipient uNGAL predicted DGF with an AUC of 0.750 (CI 
0.663–0.837, p<0.0001). At the optimal cut off  level of 560ng/ml, the sensitivity was 68% and the 
specifi city 73%. Recipient day-1 sNGAL predicted DGF with an AUC of 0.908 (CI 0.860–0.955, 
p<0.0001). At the optimal cut-off  level of 426ng/ml, the sensitivity was 91% and the specifi city 
83%. Th e diff erent cut-off  levels with sensitivities and specifi cities are shown in Table (9). Donor 
uNGAL and sNGAL failed to predict DGF. 
Figure 5. Th e day-1 uNGAL and sNGAL and donor uNGAL and sNGAL ROC curves in predicting 
DGF
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Table 9. Th e sensitivities and specifi cities of diff erent cut-off  levels of recipient day-1 uNGAL and 
sNGAL in predicting DGF
uNGAL ng/mL SensiƟ vity Specifi city sNGAL ng/mL SensiƟ vity Specifi city
17 1.00 0.04 71 1.00 0.00
210 0.97 0.35 201 0.99 0.14
408 0.82 0.59 323 0.97 0.51
560 0.68 0.73 426 0.91 0.83
866 0.34 0.84 568 0.51 0.92
1393 0.29 0.98 794 0.15 0.98
3185 0.06 1.00 1131 0.00 1.00
5.6.2  Prolonged DGF
ROC analyses were performed to assess the potential of donor and recipient uNGAL and sNGAL 
to predict prolonged DGF (Figure 6). Recipient uNGAL predicted prolonged DGF with an AUC 
of 0.748 (CI 0.654–0.842, p<0.0001). At the cut-off  level of 560ng/ml, the sensitivity was 70% and 
the specifi city 70%. Recipient sNGAL predicted DGF with an AUC of 0.825 (CI 0.751–0.899, 
p<0.0001). At the optimal cut-off  level of 486ng/ml, the sensitivity was 80% and the specifi city 
75%. Th e diff erent cut-off  levels with sensitivities and specifi cities are shown in Table 10. Donor 
uNGAL and sNGAL failed to predict prolonged DGF. 
Figure 6. Th e day-1 uNGAL and sNGAL and donor uNGAL and sNGAL ROC curves in predicting 
prolonged DGF
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Table 10. Th e sensitivities and specifi cities of diff erent cut-off  levels of recipient day-1 uNGAL and 
sNGAL in predicting prolonged DGF
uNGAL ng/mL SensiƟ vity Specifi city sNGAL ng/mL SensiƟ vity Specifi city
17 1.00 0.08 83 1.00 0.01
210 1.00 0.29 201 1.00 0.13
408 0.92 0.52 323 1.00 0.37
560 0.83 0.66 486 0.77 0.74
866 0.31 0.80 568 0.50 0.80
1393 0.23 0.93 794 0.23 0.96
3185 0.06 1.00 1075 0.04 1.00
5.6.3  NGAL in cases with clinically hiding DGF
We wanted to study whether NGAL could separate DGF cases from all cases expected to have 
EGF on the basis of fl uent urine output and decreasing creatinine. In total, 86 patients had a 
50μmol/L or greater decrease in plasma creatinine from pretransplant to day 1 and 19/86 had 
DGF. Th e mean uNGAL concentration (1318ng/mL SD 1246) and sNGAL concentration 
(604ng/mL, SD 206) were signifi cantly higher in the DGF group compared to the EGF group 
(uNGAL 398ng/mL, SD 340, p<0.0001 and sNGAL 309ng/mL, SD 125 p<0.0001). Day-1 uNGAL 
predicted DGF in this subgroup with an AUC of 0.744 (CI 0.570–0.918, p=0.014). Day-1 sNGAL 
predicted DGF in this subgroup with an AUC of 0.915 (CI 0.840–0.990, p<0.0001).
Altogether, 112 patients had a urine output (UOP) of >1L on day 1 aft er transplantation and 
15 of these had DGF. Th eir mean uNGAL concentration (1217ng/mL, SD 1229) and sNGAL 
concentration (572ng/mL, SD 207) were signifi cantly higher than those in the EGF group 
(uNGAL 460ng/mL, SD 481, p<0.0001 and sNGAL 325ng/mL, SD 136, p=0.016). Day-1 uNGAL 
predicted DGF in this subgroup with an AUC of 0.696 (CI 0.526–0.866, p=0.034). Day-1 sNGAL 
predicted DGF in this subgroup with an AUC of 0.874 (CI 0.757–0.991, p<0.0001).
5.7  DGF risk factors (I–III)
In a multivariate analysis of DGF risk factors, mode of dialysis and recipient day-1 sNGAL, 
uNGAL and UOP appeared as independent risk factors for DGF (Table 11). 
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Table 11. Multivariate analysis of diff erent parameters in predicting DGF in studies I, II, and III 
Donor study
Study I
p-value
uNGAL study
Study II
p-value
sNGAL study
Study III
p-value
Donor age (years) 0.320 0.315 0.707
Donor creaƟ nine (μmol/L) 0.807 0.891 0.622
Donor eGFR (mL/min) 0.910 0.600 0.751
Donor uNGAL (ng/mL) 0.315
Donor sNGAL (ng/mL) 0.881
Expanded criteria donors 0.650 0.484 0.929
Cold ischemia Ɵ me (hours) 0.581 0.980 0.063
Recipient age (years) 0.261 0.958 0.994
Mode of dialysis 0.012 0.004 0.042
Time on dialysis pre-TX (days) 0.431 0.457 0.721
ΔcreaƟ nine (pre-TX to day 1) 0.891 0.586
Recipient day-1 UOP (mL) <0.0001 <0.0001
Recipient day-1 uNGAL (ng/mL) 0.019
Recipient day-1 sNGAL (ng/mL) <0.0001
uNGAL=urine neutrophil gelatinase-associated lipocalin, sNGAL=serum neutrophil gelatinase-
associated lipocalin, eGFR=estimated glomerular fi ltration rate, tx=transplantation
5.7.1  Risk factors for prolonged DGF
In a multivariate analysis of prolonged DGF risk factors, donor uNGAL and recipient day-1 
sNGAL, uNGAL and UOP remained as independent risk factors for prolonged DGF in all three 
studies. In addition, donor eGFR was an independent risk factor in Study I and mode of dialysis 
in Study II (Table 12). 
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Table 12. Multivariate analysis of diff erent parameters in predicting prolonged DGF in studies I, II, 
and III
Donor study
Study I
p-value
uNGAL study
Study II
p-value
sNGAL study
Study III
p-value
Donor age (years) 0.523 0.392 0.405
Donor creaƟ nine (μmol/L) 0.152 0.997 0.867
Donor eGFR (mL/min) 0.016 0.635 0.113
Donor uNGAL (ng/mL) 0.001
Donor sNGAL (ng/mL) 0.096
Expanded criteria donors 0.038 0.563 0.119
Cold ischemia Ɵ me (hours) 0.066 0.754 0.416
Recipient age (years) 0.985 0.653
Mode of dialysis 0.321 <0.0001 0.861
Time on dialysis pre-TX (days) 0.460 0.457 0.867
ΔcreaƟ nine (pre-TX to day 1) 0.871 0.930
Recipient day-1 UOP (mL) <0.0001 0.001
Recipient day-1 uNGAL (ng/mL) 0.02
Recipient day-1 sNGAL (ng/mL) 0.042
uNGAL=urine neutrophil gelatinase-associated lipocalin, sNGAL=serum neutrophil gelatinase-
associated lipocalin, eGFR=estimated glomerular fi ltration rate, tx=transplantation
5.8  Diﬀ erences in DGF groups depending on the used DGF 
defi niƟ on
Using the Halloran et al. (268) defi nition, DGF was seen in 70/176 recipients. Using the 
conventional defi nition, DGF was seen in 66/176 recipients. Th ere were 10 recipients categorized 
diff erently depending on the used defi nition for DGF (Table 13). Th ere were three patients 
with prompt function who required one dialysis due to high potassium levels or fl uid overload 
(classifi ed as EGF using the Halloran criteria and DGF using the conventional criteria). Th eir 
sNGAL levels were <400ng/ml. Th ere were seven patients who had poorly declining plasma 
creatinine without a need for dialysis (classifi ed as DGF using the Halloran criteria and EGF 
using the conventional criteria) who all had sNGAL levels >400ng/ml. Th ere were no trends or 
signifi cant diff erences between these groups in day-1 uNGAL or day-1 UOP levels or changes in 
uNGAL, sNGAL or creatinine levels from pretransplant to day 1.
Results
46
Table 13. Th e 10 patients categorized diff erently to DGF and EGF groups depending on the used 
DGF defi nition. 
PaƟ ent DGF
Halloran Conv.
UOP 1d Δcrea
0d–1d
uNGAL 
1d
ΔuNGAL
0d–1d
sNGAL 
1d
ΔsNGAL
0d–1d
1 EGF DGF 1750 -98 455 -2904 374 -160
2 EGF DGF 1710 -264 106 - 198 -521
3 EGF DGF 1670 -60 96 - 221 -202
4 DGF EGF 430 -272 2433 - 604 -266
5 DGF EGF 2090 -74 3600 -2359 722 -75
6 DGF EGF 2060 -319 416 - 759 -203
7 DGF EGF 1330 -67 - - 971 +15
8 DGF EGF 100 -83 711 - 657 -135
9 DGF EGF 2350 -11 217 -134 451 -
10 DGF EGF 1030 +88 642 - 706 -
DGF=delayed graft  function, UOP=urine output, uNGAL=urine NGAL, sNGAL=serum NGAL, 
conv=conventional
5.9  Timing of day-1 sampling
Th e timing of sampling was not standardized. Th e day-1 serum samples were taken in the 
transplant unit the morning following transplantation on the fi rst laboratory round. Th e mean 
time from reperfusion to sampling was 11.8 hours (SD 5) ranging from 2 to 24 hours aft er 
reperfusion. We divided the patients into the following groups depending on the timing of 
sampling: <6hours (n=18), 7–12 hours (n=82), >12 hours (n=70) and analyzed whether timing 
had any infl uence on the predictive power (Table 14). Serum NGAL best predicted DGF in the 
group with the shortest time from reperfusion to sampling. However, the predictive power was 
good and roughly at the same level at all time points. 
Table 14. Timing of day 1 sNGAL samples
Mean sNGAL ng/
ml EGF (SD)
Mean sNGAL ng/
ml DGF (SD)
p-value 
DGF vs EGF
ROC-analysis AUC, p-value, CI
OpƟ mal cut-oﬀ , sensiƟ vity, 
specifi city
<6 hours n=9
278 (78.8)
n=9
687 (239.4)
0.002 1.00, p=0.001, CI 1.00–1.00
436ng/ml, 100%, 100%
7 to 12 hours n=46
365 (159.5)
n=36
594 (169.2)
<0.0001 0.864, p<0.0001, CI 0.783–0.946
420ng/ml, 94%, 73%
>12 hours n=47
321 (125.0)
n=23
526 (187.9)
<0.0001 0.920, p<0.0001, CI 0.838–0.999
420ng/ml, 91%, 83%
Th e day-1 urine samples were taken by the nursing staff  in the morning following transplantation. 
Th e exact time of sampling was not recorded, and hence the above analysis is not possible.
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5.10  Liver transplant recipients (IV)
Th e characteristics of 203 liver transplant recipients are shown in Table 15. Th e majority of the 
patients received liver transplantation due to chronic liver disease: primary sclerosing cholangitis 
(n=38), alcoholic cirrhosis (n=32), primary biliary cirrhosis (n=16), hepatocellular carcinoma 
(n=18), autoimmune cirrhosis (n=10), viral hepatitis (n=7), or other (n=44). Th e remaining 
recipients had acute liver failure (n=38). Two patients needed a re-transplantation and six 
patients died during the follow up time. 
Table 15. Th e characteristics of liver transplant patients
Number of paƟ ents 203
Age, years (SD) 49.3 (12)
Gender, female (n, %) 100 (49%)
Liver failure (n, %)
Acute
Chronic
38 (19%)
165 (81%)
Pre-TX laboratory results
Plasma creaƟ nine at lisƟ ng, μmol/L (SD)
eGFR at lisƟ ng, mL/min (SD)
90 (61)
86 (34)
Pre-TX RRT (n, %) 36 (18)
TX day laboratory results
Plasma creaƟ nine, μmol/L (SD)
eGFR, mL/min (SD)
CystaƟ n C, mg/L (SD)
Bilirubin, μmol/L (SD)
INR (SD)
Albumin, g/L (SD)
93 (64)
83 (36)
1.4 (0.8)
113 (145)
2.0 (1.6)
32 (7)
MELD score at TX day (SD) 16 (10)
AnhepaƟ c Ɵ me, min (SD) 59 (18)
PerioperaƟ ve bleeding, L (SD) 4.2 (3.6)
Lactate at day 1, mmol/L (SD) 1.5 (1.4)
IL-2R anƟ body inducƟ on (n, %) 30 (15)
Excessive exposure to CNI (n, %) 107 (53)
Highest value during fi rst TX week
Bilirubin, μmol/L (range)
Alanine aminotransferase U/L (range)
INR (SD)
73 (13-490)
316 (51-8850)
1.7 (0.5)
PaƟ ent survival at 90 days (n, %) 197 (97)
TX=transplantation, eGFR=estimated glomerular fi ltration rate, RRT=renal replacement therapy, 
MELD= model for end-stage liver disease, IL-2R=interleukin 2 receptor, CNI=calcineurin inhibitor
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5.11  Kidney funcƟ on aŌ er liver transplantaƟ on (IV)
Th e kidney function of the liver transplant recipients is shown in Table 16. Aft er transplantation, 
17% of patients needed RRT. At three months aft er transplantation, 42% had eGFR<60mL/
min and 8/203 (4%) eGFR <30mL/min. Two patients remained on RRT at three months aft er 
transplantation.
AKI occurred in 66/167 (40%) patients without the need for pretransplant RRT. AKI during the 
fi rst week aft er transplantation associated with a 20% increase of eGFR <60mL/min; in other 
words, 57% of patients with AKI during the fi rst week aft er transplantation had eGFR <60mL/
min at three months compared to 37% of those without AKI (p=0.018).
Altogether, 81/203 patients had eGFR<60mL/min before liver transplantation and 36/203 (18%) 
patients received pretransplant RRT for a mean of four days (range 1 to 18 days). Posttransplant 
RRT was needed in 22/81 patients with a pretransplant eGFR of <60mL/min. At three months 
aft er transplantation, 39/81 (48%) had an eGFR <60mL/min. Of those needing pretransplant 
RRT, 11/36 (31%) also needed posttransplant RRT and 11/36 (31%) had eGFR of <60mL/min at 
three months aft er transplantation.
Table 16. Kidney function aft er liver transplantation
Highest creaƟ nine during fi rst week aŌ er transplantaƟ on, μmol/L 173 (106)
Lowest GFR during fi rst week aŌ er transplantaƟ on, mL/min 45 (27)
Pre-TX NGAL, ng/mL 154 (141)
Acute kidney injury (n, %) 66 (40)
Need for renal replacement therapy within 90 days aŌ er transplantaƟ on (n, %) 35 (17)
eGFR at 90 days aŌ er transplantaƟ on
>60mL/min (n, %)
<60mL/min (n, %)
113 (58)
82 (42)
5.11.1  Cysta? n C 
Th e mean cystatin C concentration at transplantation was 1.6mg/L (range 0.6 to 8.1). Th e 
mean cystatin C concentration was signifi cantly higher (2.5mg/L, SD 1.3) in patients with 
eGFR <60mL/min at the time of transplantation compared to patients with eGFR >60mL/
min (1.1mg/L, SD 0.4, p<0.0001). Th ere was no signifi cant diff erence in the mean cystatin C 
concentration in patients needing pretransplant RRT (3.0mg/L, SD 1.9) compared to those 
without the need for RRT (2.2mg/L, SD 0.7, p=0.06). On transplant day, in patients without the 
need for pretransplant RRT, cystatin C based eGFR correlated fairly well with creatinine based 
eGFR (R=0.71, p<0.0001). At three months aft er transplantation in all patients the correlation 
was similar (R=0.61, p<0.0001). 
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5.11.2  Pretransplant plasma NGAL 
Th e mean pNGAL in all patients was 168ng/ml (range 60 to 1050). Th e correlation of pNGAL 
with creatinine (R=0.50, p<0.0001), cystatin C (0.54, p<0.0001), creatinine based eGFR (0.44, 
p<0.0001), and cystatin C based eGFR (R=0.38, p<0.0001) was modest. 
Th e mean pNGAL was signifi cantly higher (289ng/ml, SD 237) in patients with eGFR <60 mL/
min at the time of transplantation compared to patients with eGFR >60mL/min (108ng/ml, SD 
57, p<0.0001). In patients with pretransplant GFR <60mL/min pNGAL was signifi cantly higher 
among those needing RRT (434ng/ml, SD 301), compared to those without the need for RRT 
(214ng/mL, SD 152, p=0.002). 
Th ere were no signifi cant diff erences in the mean pNGAL concentrations between patients with 
(136ng/mL, SD 140) or without (112ng/mL, SD 64, p=0.26) posttransplant AKI or with (212ng/
mL, SD 226) or without (159ng/mL, SD 151, p=0.33) the need for posttransplant RRT. Th e mean 
pNGAL was signifi cantly higher among patients with eGFR <60mL/min at three months aft er 
transplantation (202ng/mL, SD 198) compared to those with eGFR >60mL/min (141ng/mL, SD 
125, p=0.001).
We assessed the risk factors predicting eGFR<60mL/min at three months aft er transplantation 
in a multivariate analysis. Recipient age, IL-2R induction therapy, AKI during the fi rst week 
aft er transplantation, highest alanine aminotransferase concentration during the fi rst week aft er 
transplantation, and pNGAL >260ng/mL emerged as independent risk factors. Th e cut-off  for 
pNGAL was set at 260ng/mL, as this is the threshold of normal and high pNGAL concentrations, 
as reported by the manufacturer. 
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6.  DISCUSSION
NGAL has been found to be the earliest and highest upregulated gene in acute kidney injury 
caused by various insults, such as IRI or toxic nephropathy, preceding the classical markers of 
kidney injury such as creatinine (14, 220, 269, 270). AKI in the form of DGF is a considerable and 
growing problem aft er kidney transplantation as older recipients and donors with comorbidities 
are increasingly accepted for transplantation (74, 75, 271). DGF is diagnosed on a wait and see 
basis, and hence the diagnosis is oft en too late. NGAL has been proposed as a diagnostic tool for 
DGF. We hypothesized that measuring NGAL could help in assessing donor kidney quality and 
predicting DGF aft er kidney transplantation and kidney function aft er liver transplantation. 
Study I is the fi rst published study where urine and serum NGAL concentrations were 
systematically and prospectively measured from brain-dead donors. We found that sNGAL 
concentrations were high in all donors whereas uNGAL concentrations were mostly low. Brain 
death is a major, systemic condition aff ecting most vital functions. Hence, it is natural that the 
sNGAL levels in the donors were high and did not correlate with kidney function in the recipient. 
Donor sNGAL probably originates from various organs and does not describe kidney function 
in the donor; this is why donor sNGAL did not correlate with DGF.
Increased uNGAL can derive from increased systemic NGAL production that overrides the 
reabsorption capacity, impaired megalin dependent reabsorption in the proximal tubulus, or de 
novo synthesis of NGAL in the kidney (229). Many studies have shown that in the kidney NGAL 
is mainly synthetized in the loop of Henle and distal nephron in response to injury, despite the 
fact that the major site of acute kidney injury is the proximal tubulus (235, 236, 243, 272, 273). In 
CKD most of the uNGAL derives from impaired reabsorption. However, irrespective of the cause, 
in AKI the GFR decreases, limiting NGAL fi ltration and reabsorption, and most of the uNGAL 
originates from the distal nephron (220, 229, 243). Th is could explain why the donor uNGAL 
concentrations were mostly low: sNGAL originates from other organs than the kidneys, NGAL 
is fi ltered and reabsorbed by the donor’s healthy kidneys and very little is excreted. When donor 
uNGAL is increased, it indicates damage in the donor kidney, and hence we can see a correlation 
with prolonged DGF. We found that high donor uNGAL associated with a higher CADI score, 
supporting the association. As IRI and recipient factors have a major impact on DGF and graft  
survival, a perfectly normal donor kidney can be damaged later in the transplantation process. 
However, high donor uNGAL concentration might refl ect problems aft er transplantation and 
help with decision-making in complicated or borderline cases. 
Th e only studied donor parameter aff ecting donor NGAL concentration was ADH treatment, 
which seemed to decrease NGAL levels. Vasopressin administration results in increased 
aquaporin-2 receptor concentration on distal tubule and collecting duct cells and water is 
progressively reabsorbed. It also increases peripheral resistance and hence increases blood 
pressure and improves hemodynamic stability (274), which could lead to increased renal 
perfusion pressure and better renal function and thus decrease uNGAL concentration. It is 
possible that better hemodynamic stability additionally decreases NGAL secretion in other 
organs, resulting in decreased sNGAL concentration. We could also speculate on the eff ect of 
vasopressin on de novo NGAL synthesis as NGAL originates from the distal tubule. 
Discussion
51
Since our study was published, there have been three other publications where the association 
of donor NGAL with DGF has been studied. Buemi et al. found that neither donor pNGAL 
nor uNGAL in 80 deceased and 17 living donor transplantations predicted kidney function 
aft er transplantation. Th ey defi ned kidney function as reaching eGFR>40mL/min or serum 
creatinine<2mg/dL(=176μmol/L) (29). Donor sNGAL could not predict DGF, defi ned as 
the need for dialysis during the fi rst week aft er transplantation, in a more recent study of 159 
deceased donors (275). A panel of urinary biomarkers (Kim-1, NGAL, IFN-γ, TNF-α) was 
tested in another study of 182 deceased donors. Th e authors found that Kim-1 but not the other 
markers may be helpful in predicting AKI aft er transplantation (276). Th ese fi ndings are in line 
with our study. However, the other studies did not analyze the relationship of donor NGAL and 
prolonged DGF, which was the main fi nding in our study.
In studies II and III we investigated the role of recipient urine and serum NGAL in the prediction 
of DGF. Th e pretransplant levels were measured to get an idea of NGAL levels in ESRD patients 
on dialysis and to be used as a reference for posttransplant measurements. Th e pretransplant 
sNGAL concentration was signifi cantly lower in patients with good residual diuresis. It is 
probable that the nonfunctioning kidneys excrete NGAL due to ongoing damage, which is then 
secreted into the circulation, resulting in high pretransplant serum and urine NGAL levels in all 
recipients. As the kidneys do not function, NGAL, originating from the kidney and other organs, 
circulating back to the kidney is not reabsorbed and the uNGAL concentration remains high. 
However, in those with fl uent copious diuresis from their native kidneys, some of the systemic 
NGAL is fi ltered through the glomerulus but not reabsorbed and instead fl ushed away, resulting 
in lower sNGAL levels. Th is diff erence was not seen in uNGAL, which is consistent with the 
presumption that the majority of the uNGAL derives from the kidneys and is not aff ected by the 
amount of water diuresis.
Aft er transplantation, both urine and serum NGAL levels decreased as the transplanted kidneys 
started to function as expected. Th e serum and urine NGAL concentrations were signifi cantly 
higher in the DGF group as soon as the following morning aft er transplantation. It is most likely 
that the new kidney clears NGAL secreted by the native kidneys. Aft er transplantation, the native 
kidneys shut down resulting in a decrease in water diuresis and probably NGAL secretion. It 
has previously been shown that NGAL expression is reversible and ceases when the inducing 
stimulus is removed (243).  
In ROC analyses, sNGAL predicted DGF and prolonged DGF well, uNGAL moderately, and 
they emerged as independent DGF risk factors in a multivariate analysis. Th is fi nding further 
supports their usefulness in predicting DGF. Th e inferior ability of uNGAL in predicting DGF 
might result from the signifi cant number of missing samples. Furthermore, the urine excreted 
very soon aft er transplantation is a mixture produced from the native and the transplanted 
kidneys, and it is also possible that the composition (e.g. high protein concentration) of the 
urine aff ects the uNGAL concentration or interferes with the detection method. We did not 
standardize uNGAL concentration to creatinine. Urine creatinine excretion is not constant and 
normalizing a biomarker concentration to creatinine results in under- or overestimation of the 
biomarker concentration, depending on the clinical situation, and complicates the determination 
of a threshold concentration. It has therefore been suggested that all urine biomarkers should be 
measured as such instead of proportioning them to creatinine (277).
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In addition to our studies, so far there are nine published studies investigating the role of serum/
plasma NGAL and ten to the role of uNGAL in prediction of DGF/AKI aft er transplantation. 
Serum/plasma NGAL was found useful in the prediction of DGF/AKI in eight publications (24, 
26–28, 29, 34, 37, 38). Th e AUCs varied from 0.82 to 0.97 and the optimal cut-off  value ranged 
from 233ng/ml to 500ng/ml, which is in line with our study. Some studies did not report AUCs. 
Th e results concerning uNGAL are not so clear. Seven publications showed that uNGAL is 
predictive of AKI with an AUC ranging from 0.75 to 0.9 and the optimal cut-off  value from 255g/
ml to 560ng/ml; in two studies uNGAL did not predict DGF (22, 25, 29–34, 36). Comparing data 
is impossible in some cases, as some authors did not report AUCs and in some cases uNGAL was 
normalized according to urine creatinine. 
Additionally, sNGAL and uNGAL have been found to be of value in predicting acute rejection 
aft er transplantation (278, 279). Neither serum nor urine NGAL correlated with rejections in our 
studies but the number of patients with rejection was so small that no conclusions can be drawn. 
Additionally, there are a few other publications dealing with NGAL and kidney transplantation. 
Fonseca et al. and Choi et al. found that uNGAL predicts 1-year graft  survival but Nauta et al. did 
not fi nd any association with NGAL and graft  loss aft er transplantation, which is in line with our 
results (27, 32). 
Kaufeld et al. studied whether uNGAL normalized to creatinine correlated with fi ndings 
in protocol biopsies at three weeks, three months, and six months aft er transplantation in 
140 randomly chosen protocol biopsies, but could not fi nd a link (35). In the fi rst study ever 
published on NGAL and kidney transplantation, Mishra et al. stained NGAL in biopsies taken 
one hour aft er reperfusion and found that the intensity of NGAL staining correlated with peak 
postoperative creatinine and DGF (280). We found that donor uNGAL correlated with CADI 
score in donor biopsy. We did not study the correlation of NGAL and recipient biopsies. 
Perioperative AKI and renal impairment at three months aft er transplantation are important risk 
factors for CKD and ESRD aft er liver transplantation (6, 281, 282). In our study, 40% of patients 
had AKI during the fi rst week aft er liver transplantation, and 42% had moderate or worse 
kidney dysfunction at three months, thus resembling previously published rates using similar 
defi nitions (282–284). Patients with perioperative AKI have been shown to benefi t from delayed 
CNI initiation and hence it would be very important to identify these patients early (285). Also, a 
combined liver–kidney transplantation could be performed for those who will remain dependent 
on RRT aft er liver transplantation (286). Th e problem is that it is currently impossible to identify 
these patients in advance.
Signifi cant hope has been put on NGAL in predicting AKI and it has been proposed as a 
marker for AKI aft er liver transplantation. To date, there are 12 studies investigating the role of 
serum, plasma or urine NGAL in the prediction of AKI aft er liver transplantation (39–50). Th e 
number of patients in the studies varies from 19 to 107. All studies found that NGAL is useful in 
predicting AKI aft er liver transplantation. Th e AUCs varied from 0.68 to 0.87, but some studies 
did not report AUCs. In two studies NGAL was found to correlate with the severity of AKI (40, 
41). However, in all of these studies the sample was taken aft er transplantation, which is too late 
for a combined kidney–liver transplantation and delayed CNI initiation would have already been 
done.
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We were not able to predict posttransplant AKI or the need for posttransplant RRT by measuring 
pretransplant NGAL. Pretransplant NGAL has been studied in one other publication and, in 
line with our fi ndings, it failed to predict posttransplant AKI (39). However, we found that in 
patients with impaired kidney function before transplantation, high pretransplant NGAL 
concentration was an independent risk factor for ongoing kidney dysfunction at three months 
aft er transplantation. High pretransplant NGAL concentration refl ects the recipients’ kidney 
quality and these patients are at increased risk for further kidney injury. Although no treatment 
as such exists, optimizing and individualizing patient care can avoid further damage. 
Th ere are several limitations in these studies that need to be addressed. First, although this is 
a nationwide study, it is a single center study with a limited number of patients. Th e timing of 
sampling from kidney recipients was not standardized precisely enough in any of the studies 
apart from donor uNGAL collection. Based on the results it would have been interesting to see 
whether very early sampling timing would have yielded better predictive power. In Study III 
it would have been better to use plasma instead of serum. In fact, it would have been best to 
collect plasma instead of serum as serum can be extracted from plasma but not the other way 
around. Moreover, we only tested one biomarker in studies I–III instead of a panel of biomarkers. 
Lack of urine as sample material for NGAL analyses and lack of data on UOP, proteinuria and 
urine sodium concentration are important limitations in Study IV. Confounding eff ects of, for 
example, dialysis, MARS treatment, surgery, anesthesia, medication, or urine composition on 
NGAL concentration and analysis methods are not known and could not be eliminated. 
Recently, it has been shown that NGAL exists in diff erent forms. Western blot has revealed 
that diff erent forms of NGAL can be detected with diff erent methods based on their molecular 
weight. Cai et al. found that monomeric NGAL is suggestive of AKI and secreted by kidney 
epithelial cells, whereas dimeric NGAL originates from neutrophils (287, 288). So far it is unclear 
which forms of NGAL the currently available tests detect, apart from western blot, so it is 
possible that this aff ects the results. Additionally, the serum and urine NGAL concentrations are 
not comparable as the detection method is diff erent.  
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7.  CONCLUSIONS 
1. High donor urine NGAL is an independent risk factor for prolonged DGF (I).
2. Recipient urine NGAL on the fi rst day aft er kidney transplantation predicts DGF and 
prolonged DGF with moderate sensitivity and specifi city (II).
3. Recipient serum NGAL on the fi rst day aft er kidney transplantation predicts DGF and 
prolonged DGF. It also predicts DGF in cases expected to have early graft  function based 
on clinical fi ndings (III).
4. Th e independent risk factors for DGF and prolonged DGF are day-1 serum NGAL, 
day-1 urine output and mode of dialysis before transplantation (II, III). 
5. Plasma NGAL before liver transplantation associates with reduced kidney function at 
three months aft er transplantation (IV).
Conclusions
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